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Introduction
Philipe Mouret performed the first laparoscopic cholecystectomy in 1987, and 
since then it has become the ‘gold standard’ treatment for symptomatic gallstones. It 
had undoubted benefits over the conventional open procedure, such as reduced 
morbidity and mortality, a shorter hospital stay and quicker return to normal daily 
activities. This improved risk to benefit ratio has seen an increasing number of 
cholecystectomies performed, without a parallel increase in the prevalence of 
gallstones. This could represent a higher patient demand for ‘key hole’ surgery, or a 
reduced threshold for intervention, with surgery being performed for poorly defined 
indications such as functional gastrointestinal disorders.
Independent of the operative technique, there is a significant proportion of 
patients who complain of persistent symptoms after cholecystectomy, a condition 
described as postcholecystectomy syndrome. There is evidence to show that patients 
who experience a predominance of functional symptoms such as altered bowel habit 
and those requiring psychotropic medications have a higher rate of persistent 
symptoms following surgery.
Irritable bowel syndrome is a functional colonic disorder characterised by 
abdominal discomfort, along with altered defaecation or change in bowel habit. Many 
of the symptoms of IBS overlap with those of functional dyspepsia or gallstones, and 
a higher rate of anxiety and depression has been observed in this group. As yet there is 
no study to show that patients with irritable bowel syndrome and gallstones have a 
worse outcome after cholecystectomy, but population based studies have shown that 
they do have a higher rate of cholecystectomy when compared with the general
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population. A significant proportion of these patients may be having 
cholecystectomies for symptoms of colonic rather than biliary origin. If we could 
predict patients who were less likely to benefit from surgery, and treat them 
expectantly, there would be financial gains and benefits in terms of patients’ health 
from reduced morbidity by unnecessary surgery.
Quality of life assessment is a measurement tool that researchers can use to 
investigate outcome after an intervention or treatment. Methods of assessing quality 
of life and its clinical application have gained popularity and improved significantly 
over the last decade. In this study, quality of life measurement is the principle means 
used to examine what effect irritable bowel syndrome has on outcome after 
laparoscopic cholecystectomy.
Section 1
QUALITY OF LIFE AND GALLSTONES
The physicist Lord Kelvin (1824-1907)
“When you can measure what you are speaking of and express it in terms of 
numbers you know something about it: when you cannot express it in terms of 
numbers your knowledge is of a meagre kind”
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Chapter 1
Quality of Life Measurement
1.1 Introduction
In an era when evidence based medicine and revalidation are at the forefront 
of clinical practice and where governments, the public and indeed the media are 
becoming increasingly critical of how patients are treated, it has become essential to 
provide evidence for the benefits of surgical intervention. Traditionally, outcome 
measurements in surgery have focused on Figures such as morbidity rates, disease 
free periods, length of hospital stay, recurrence rates and of course, mortality 
(O'Boyle, 1992; Fraser, 1993). Quality of life (QOL) is an alternative and valuable 
tool which researchers can use to measure outcome after surgery. In terms of 
medicine, it allows objective measurement of the effects an illness or treatment can 
have on a patient’s daily life and life satisfaction; that is, it can be used to evaluate 
human and financial costs. Its assessment in the medical arena has dramatically 
increased in popularity over the last decade. This trend has been observed in the 
surgical literature. In 1992 a Scottish group simply looked at the number of QOL 
studies in surgery cited on Medline. They found an exponential rise in published 
articles over the previous two decades. Their Figures ranged from 92 cited between 
1975 and 1977, to over 2 thousand cited between 1996 and 1998 (Camilleri-Brennan 
and Steele, 1999). As we shall discuss, QOL is more often mentioned than measured 
accurately (Wood-Dauphinee, 1996).
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1.2 Quality of life - the concept
Quality of life is not a new concept; it was first defined by the World Health 
Organisation (WHO) in 1948 as not only the absence of disease and infirmity , but 
also the presence of physical, mental and social wellbeing (Constitution of the World 
Health Organisation, 1952). This definition is not all encompassing and by no means 
has universal acceptance (O'Boyle. 1992; Olschewski et al., 1994; Camilleri-Brennan 
and Steele, 1999). More recently, the WHO quality of life group have expanded this 
further to incorporate how an individual’s cultural and social value system and their 
goals and expectations may influence global QOL (World Health Organisation 
Quality of Life Group, 1996).
In terms of medicine, health related quality of life (HRQOL) aims to 
objectively quantify these factors by measuring subjective attitudes and experiences 
of physical, social and emotional health (Guyatt et al., 1993; Testa and Simonson, 
1996). Estimating a patient’s perspective of their own health status acts as a powerful 
tool to assess and explain disease outcome. For this reason QOL measurements are 
often the endpoint of clinical trials and outside the medical arena can incorporate non­
health related elements, such as personal finances, leisure time and housing issues 
(Langenhoff et al., 2001). Potential application of obtained results include 
identification of problems with individual patients or within populations, evaluation 
of treatment efficacy, implementation of policy, assessment of quality of health care, 
economic evaluation and improvement of disease knowledge (Fitzpatrick et al., 1992; 
Borgaonkar and Irvine, 2000)
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Whatever the definition, it is largely agreed that QOL is a complex 
multidimensional concept made up from three principle domains: physical, 
psychological and social (O'Boyle, 1992; Fitzpatrick et al, 1992; Olschewski et ai, 
1994; Testa and Simonson, 1996). The physical domain measures how illness affects 
a patient’s perception of his or her own bodily function. The psychological domain 
includes aspects of a patient’s emotional and mental wellbeing such as mood, anxiety, 
concerns, fear and anger. Finally, the social domain refers to how a patient interacts 
with and is incorporated into their social role, for example relationship with family, 
integration into the workplace and spiritual aspects. Each of these domains can be 
measured in two dimensions: objective assessments of function or health (the Y axis 
in Figure 1) and more subjective perception of health (the X axis). The patient’s 
subjective perception translates the objective assessment into the actual QOL 
experienced (or Q in Figure 1). In other words, the global quality of life score or 
value takes into account the subjective perception and objective measurements of each 
of these items (Bergner, 1989; Testa and Simonson, 1996). Subjective perceptions of 
health vary greatly between individuals and are influenced by many factors such as 
previous experience, family support, and financial security. Two people with exactly 
the same health profile may have very different qualities of life. For example one 
individual with Crohn’s disease may hold down full-time employment, have an active 
family and social lifestyle, while another patient with the same disease extent and 
severity may be depressed, unemployed and unable to fulfil their role in the home 
environment.
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Every domain can be further subdivided into different components, for 
example symptoms, ability to function and disability, within the physical domain. 
These components can be measured in isolation or collectively. Many of these 
components cannot be observed directly; they are typically evaluated according to the 
principles of item-measurement theory (Lord. 1980). This theory proposes that there 
is a single true QOL value, Q, that cannot be measured directly, but that can be 
measured indirectly by asking a series of questions called ‘items’ . In Figure 1, Z 
represents this observed or measured value. If the items have been chosen properly, 
the resulting scale of measurement, Z, should differ from the true value, Q, only by 



















Figure 1. Conceptual scheme of the domains and variables involved in a quality of 
life assessment.
The x axis represents subjective perceptions of health, the y axis objective health 
status, the coordinates Q(X,Y) the actual quality of life, and Z the measurement of the 
actual quality of life associated with a specific component (e.g. positive affect) or 
domain (e.g. the psychological domain).
6
QOL is also dynamic (Bergner, 1989; Olschewski et al., 1994), that is it varies 
with respect to time. It can change from day to day or even from hour to hour and for 
this reason it is best to measure changes in quality of life over time. This is 
particularly useful when evaluating the effects of treatment on disease. Assessments 
can be made before, and at regular intervals during and after, treatment to gauge 
treatment efficacy, disease regression or recurrence.
1.3 Measuring quality of life
Quality of life measurements usually take the form of a structured 
questionnaire commonly known as an instrument, which has been specially designed 
to assess each of the three domains. The patient’s answers are scored, allowing 
qualitative information to be converted to quantitative data (Guyatt et al., 1993; 
Camilleri-Brennan and Steele, 1999). Each domain can be scored separately or 
globally, giving a single quality of life index. Variation between instruments usually 
relates to how questions are formatted, how much and to what extent they emphasise 
each domain and to the degree of subjectivity involved.
1.3.1 Types of Instruments
There are three main types of instrument available (Moyer and Fendrick, 
1998; Borgaonkar and Irvine, 2000), the global , the generic and the disease or 
symptom specific . An example of a global instrument would be a visual analogue 
scale. This is a graded scale from 1 to 10, and used most frequently in clinical practice 
to assess pain. They themselves are simple and quick to administer, giving an instant 
value that can be correlated with previous results or used and then applied at that
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single point in time to assess the measured variable. The data gathered from these 
instruments is however of limited value when detailed quality of life assessment is 
needed (Testa and Simonson, 1996; Irvine, 1997; Borgaonkar and Irvine, 2000). A 
question such as “Please mark on this scale your current quality of life” would give 
Figures much too vague and imprecise to be interpreted exactly. For this reason 
clinicians and researches favour more detailed instruments that assess each domain 
separately.
Generic instruments are commonly used in clinical research. They are 
designed for application across a diverse spectrum of patients or disease populations 
(Bergner et al., 1981; Ware, Jr. and Sherboume, 1992), and are frequently used when 
a general survey of health is needed. They cover quality of life in a broad sense and 
are particularly useful where comparison between disease groups or populations is 
needed (Kaplan et al, 1989; Testa and Simonson, 1996; Camilleri-Brennan and 
Steele, 1999; Langenhoff et al., 2001). Until recently this type of instrument has been 
the predominant method for HRQOL assessment. Examples of generic instruments 
include the Short Form 36 (SF-36) (Ware, Jr. and Sherbourne, 1992), the Sickness 
Impact profile (SIP) (Bergner et al., 1981) and the Nottingham Flealth Profile (NHP) 
(Hunt et al., 1981). Despite being the best type of instrument for detecting unexpected 
disease impact, and for population comparison they do lack sensitivity and can fail to 
quantify or even identify clinically significant changes brought about by the disease 
being studied (Guyatt et al., 1993; Testa and Simonson, 1996; Borgaonkar and Irvine, 
2000).
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As the names suggests, disease or symptom specific questionnaires are 
tailored for patients with a particular disease or symptom. They focus on domains 
most relevant to the disease under study, and on the characteristics of patients in 
whom the disease is most prevalent (Testa and Simonson, 1996). Rather than a global 
health assessment they can give important information on specific areas of quality of 
life. They are particularly good when used in clinical trials to evaluate treatment 
efficacies (Guyatt et al, 1987; Guyatt et al., 1989). Overall they tend to be more 
sensitive to small changes in quality of life (Guyatt et al., 1993; Borgaonkar and 
Irvine, 2000), but can sometimes overlook unexpected effects. For this reason it is 
now becoming more common to combine both generic and disease specific 
instruments in clinical trials. Examples of disease specific questionnaires include “The 
Gastrointestinal Quality of life Index” (GIQLI) (Eypasch et al., 1995), the IBS-QOL 
(Patrick et al., 1998) and, possibly the most widely used instrument in cancer 
research, the EORTC QLQ-C30 (Fitzsimmons et al., 1999). The latter was designed 
by the European Organization for Research and Treatment of Cancer (EORTC). It 
uses a modular approach, with a core questionnaire consisting of 30 questions 
(EORTC QLQ-C30) and then additional questionnaires to focus more closely on 
specific types of cancer e.g. QLQ-PAN26 dealing with pancreatic cancer (Bassi et al., 
1999), QLQ-CR38 for colorectal cancer (Sprangers et al., 1999) and the QLQ-LC13 
used in lung cancer (Bergman et al., 1994). There are literally hundreds of disease 
specific and symptom specific questionnaires available (Berzon et al., 1995). 
However, many common diseases still have no validated instrument and for this 
reason, if inappropriate questionnaires are used, unanticipated events can be easily 
missed.
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1.3.2 Measurement properties of QOL instruments
Very definite measurement properties exist for quality of life instruments; they 
assist in the development of new instruments and ensure that they measure what they 
purport to measure both accurately and reliably. The key concepts include validity, 
reliability and responsiveness (Fletcher et ai, 1992; Muldoon et al., 1998; Cohen, 
1999) . A clear understanding of these principles is required if development of a new 
HRQOL questionnaire is to be successful (Brown, Jr., 1999) and be accepted by 
investigators.
Validity is probably the single most important property used. It aims to show 
that the instrument measures what it intends to measure and not some other factor, 
thus proving that it can be used appropriately for a particular disease or clinical 
situation. Referring back to Figure 1, validity should show that Z correctly measures 
Q. There are three main types of validity which are quoted in HRQOL validation 
papers. In brief, content validity asks whether the instrument samples the domain 
adequately and to what extent the questions comprehensively cover the population, 
disease or symptomatic state. Criterion validity compares how the new instrument 
correlates with what is commonly accepted as being the gold standard. So at 
sometime during the validation process both the new and the gold standard 
instruments are administered concurrently and the results correlated. If results 
correlate then it can be accepted that the new instrument is a valid measure of the 
disease in question. Finally, construct validity uses an approach whereby the 
instrument is tested against a hypothesis. For example, if it is predicted that a person 
with Crohn’s disease has poorer social functioning with increased disease severity, 
and low scores are measured with the new instrument in this domain, then validation
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is strengthened. When new instruments are being published, details of the validation 
process should be clearly stated, with reference to other previously validated 
instruments, if available. A good example of the validation process is seen in the 
development of the GIQLI (Eypasch et ah, 1995; Quintana et al., 2001). The authors 
showed evidence of good criterion validity when data was correlated with the Spitzer 
Quality of Life Index (SQLI) (Spitzer et al., 1981) and the Bradburn Affect Balance 
Scale (BABS) (Bradburn and Noll, 1969). They also proved construct validity in 
patients with gastrointestinal disease when looking at disease severity.
Reliability or reproducibility can be demonstrated if the questionnaire gives 
consistent results when repeatedly administered to the same individual or stable group 
of patients whose disease state has not changed with time. Again the GIQLI showed 
this when repeat testing of 25 patients after 48 hours gave similar results. There are 
three types of reliability measurement (Fletcher et al., 1992; Guyatt et al., 1993). 
Firstly, test re-test reliability which we have already mentioned. Secondly, internal 
consistency reliability that determines the extent to which a group of questions are 
measuring a particular domain and finally, inter-rater reliability which looks at the 
effects of instrument administration by different interviewers.
Responsiveness measures how well a questionnaire detects small changes in 
patient status; that is, the magnitude of change in the HRQOL score should reflect a 
similar change in the patient’s clinical state. In Figure 1 therefore, the responsiveness 
is a measure of the association between change in the observed score Z, and the 
change in the true score, Q. The GIQLI measured responsiveness on patients 
undergoing laparoscopic cholecystectomy (Quintana et al., 2001), and showed
improvement of scores as the patients’ clinical status slowly improved post- 
operatively. Responsiveness is particularly important when any instrument is used in a 
longitudinal study (Camilleri-Brennan and Steele, 1999).
1.3.3 Instrument selection
Choosing an appropriate questionnaire is an important first step, if statistically 
significant results are to be obtained. The choice of instrument depends largely on 
what type of study is being performed. Clinical trials which look at outcomes of 
treatment over time (e.g. drug trials) are more responsive to a disease specific 
questionnaire. The disease specific questionnaires are usually developed so as to 
detect subtle disease and treatment related effects, which reflect issues of importance 
to the patient. Generic instruments tend to focus on broad aspects of QOL and health 
status, and are intended for use in general populations across a wide range of disease 
conditions. For this reason they are better suited to cross sectional studies (Camilleri- 
Brennan and Steele, 1999). Many modern questionnaires use a modular approach, for 
example the EORTC QLQ-C30 (Fitzsimmons et ai, 1999) and the Functional 
Assessment of Cancer Therapy (FACT - G) (Lee et ai, 2004a). These generic 
questionnaires make up the core of questions, but have add-on disease specific 
components. This has the advantage of combining both generic and disease specific 
properties into one index.
For many disease states however, a specific questionnaire is not available and 
the most closely related instrument should be chosen. In some circumstances, a non- 
validated instrument may be available; and in these cases it is good practice to use an 
already validated questionnaire in parallel (Fletcher et ah, 1992).
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There are several resources available to help individuals find the most 
appropriate instruments) for their study. The best place to start is probably a journal 
search using Medline or a similar available search method. Over the last decade there 
has been an exponential increase in the number of publications relating to quality of 
life. In this context the most useful are probably review articles looking at already 
validated instruments in various specialist fields, for example in cancer surgery 
(Langenhoff et al., 2001), gastroenterology (Borgaonkar and Irvine, 2000) or in 
palliative care (McMillan, 1996). These types of papers give the reader an overview 
of what disease specific instruments are available in their area of interest. Yacavone et 
al recently published a review article in the American Journal of Gastroenterology, 
which discussed the most up to date generic and disease specific questionnaires 
available in their field (Yacavone et al., 2001).
There have been five publications of the ‘quality of life bibliography and 
indexes’ (Spilker et al., 1990; Berzon et al., 1995). This is an extremely useful source 
of information on QOL instruments but, unfortunately, it has not been updated since 
1994. Several detailed reviews on the methods for evaluating and selecting HRQOL 
instruments have been published. One by Shuvayu et al (Shuvayu et al., 1999) is of 
particular value. They used the selection of an asthma specific questionnaire as an 
example in their paper.
The internet is another valuable resource to aid instrument selection. Apart 
from generic search engines such as Yahoo, Altavista and Google, dedicated HRQOL 
websites exist with instrument lists and descriptions. Some sites have search facilities 
to help selection.
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The Quality of Life Instruments Database ( http://www.proqolid.org/ ) is 
probably the most comprehensive and user friendly online database available. The 
project was initiated by the Mapi Research Trust in Lyon, France. Initially called 
QOLID (Quality of Life Instruments Database), the project's purpose was to provide 
all those involved in health care evaluation with a comprehensive and unique source 
of information on HRQOL measures available through the internet. PROQOLID lists 
over 1000 questionnaires giving detailed information, including contact information 
and references on over 470. It has two types of membership; the first is free and 
includes access to information such as the objective of development, name of the 
author, type of instrument, mode of administration, target population, original 
language and the list of available translations.
3 PROQOI.il). the Patient Reported Outcome and Quality of I ife Instruments Database Microsoft Internet fxplorer
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The second section requires a subscription fee and includes full references, copyright 
and detailed contact information as well as copies of over 170 original questionnaires, 
100 translations and over 50 user manuals. PROQOLID is updated in close 
collaboration with the instruments' authors on a regular basis. Fifty or more new 
instruments are added to the database annually. The home page for the website is 
shown in Figure 2 above.
Several websites that focus on disease specific areas of medicine are available. 
http://www.atsqol.org/ - American Thoracic Society
http://www.qoltech.co.uk/ - QOLTECH website
http://www.chcr.brown.edu/pcoc/toolkit.htm - TIME
*) Toolkit Homepage Drown Univer&ity Microsoft Internet Fxptorer
File Edit View Favorites Tools Help 
QBack ’ V] <Z) Search
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tools These measurement tools should identify opportunities for improving medical care, 
examining the impact of interventions or demonstration programs, and holding institutions 
accountable for their quality of care. The Toolkit takes steps toward crossing this 
measurement barrier by creating patient-focused, family-centered survey instruments that 
address the needs and concerns of patients and their families, as defined by them.
With funding from the Nathan Cummings Foundation and the Robert Wood Johnson 
Foundation, we have assembled an authoritative bibliography of instruments to measure 
the quality of care and quality of life for dying patients and ttieir families. Based on these 
reviews, we have created the Toolkit instruments, which are available on this site at no 
charge.
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Figure 3 Toolkit of Instruments to Measure End-of-Life Care (TIME)
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The American Thoracic Society webpage is designed for researchers who are 
interested in QOL measurement for patients with respiratory disease. They give 
detailed information on over 70 relevant questionnaires. What is also very useful is 
that they subdivide questionnaires in terms of disease states, for example asthma, 
cystic fibrosis and lung cancer. They give detailed and referenced reviews of which 
QOL instruments have been used and are most useful with each condition. The 
QOLTECH website is a similar, but smaller site, concentrating solely on asthma. The 
“Toolkits of Instruments to Measure End-of-Life Care” (TIME) website, focuses on 
QOL for the dying patient (Figure 3). It is an excellent resource for practitioners and 
care givers who need information on QOL in areas related to the terminal phase of life 
e.g. pain, emotional and cognitive symptoms and functional status.
Many of the more popular and widely validated questionnaires have their own 
websites.
http://www.eortc.be/ - EORTC webpage
http://www.sf36.com/ - SF36 webpage
http://www.facit.org/ - FACIT webpage
The Functional Assessment of Chronic Illness Therapy (FACIT) website (Figure 4) is 
particularly well designed and easy to navigate. This group published its first 
questionnaire in 1993 (Celia et al., 1993), the FACT-G questionnaire which looked at 
QOL in cancer patients. Since then it has produced over 40 further instruments. It is 
one of the few generic questionnaires to work on a modular basis, but as well as 
cancer related instruments it now has questionnaires for other illnesses such as
16
multiple sclerosis and HIV. The website lists in detail the core and disease specific 
questionnaires that are available. It also provides a wide range of facilities, including 
access to validation papers, translations, scoring guidelines and database programs to 
help with interpretation.
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Figure 4 The Functional Assessment of Chronic Illness Therapy (FACIT)
Two journals devoted solely to QOL publications exist:
http://www.hqlo.com/home/
“Health and Quality of Life Outcomes” is a web-based only journal (Figure 5). It has 
on average, 5 to 10 new QOL papers published per month. Submission is online and 
peer reviewed. All accepted articles are referenced on PubMed.
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http://www.kluweronline.com/ISSN/0962-9343/CONTENTS
“Quality of Life Research” is a subscription based journal, with monthly publication. 
Again articles are peer reviewed and referenced on Medline. It is currently on its 14th 
volume and has a wealth of resources spanning the last decade.
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Finally, there are several books which extensively review generic and disease specific 
questionnaires (Bowling, 1995; Bowling, 1997). The Compendium of Quality of Life 
Instruments (Salek, 1998) can be found online at:
There is a wealth of data and resources available to help researchers choose 
the most appropriate questionnaire for their study. Some of the basic principles that 
should be considered when selecting an instrument include:
• There should be documentation concerning the development and psychometric 
properties of the instrument and in particular, concerning its validation, 
reliability, sensitivity and responsiveness.
• There should be evidence that the instrument has been developed for and 
tested in a wide range of patients with the target disease states or receiving the 
intended treatment modalities.
• Instruments should be valid for use in patients with the relevant educational, 
cultural and ethnic backgrounds.
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• If additional language versions are required, they should be developed and 
tested using formal procedures of forward and backward translation.
• If generic and disease specific questionnaires are to be combined they should 
be compatible.
• The feasibility of the study should be considered, for example length of the 
questionnaire, how long does it take to complete, how easily understood are 
the questions and are there any difficult or embarrassing questions?
• Are there reference data or interpretation guidelines available? These are 
important for analysis of results and design of the study (e.g. power 
calculation)
1.3.4 Administration of selected instrument
There are several ways that HRQOL instruments can be administered (i.e. self, 
interviewer, telephone and proxy). Most questionnaires are designed to make self 
administration straightforward. They are written in a language easily understood by 
patients, require only tick box answers and take less than 10 minutes to complete. All 
these factors are important to improve compliance and accurate data collection. There 
is however a greater risk of misinterpretation and blank questions when compared to 
an interviewer, which is recommended especially when there is a degree of cognitive 
impairment or illiteracy (Guyatt et al., 1993; Camilleri-Brennan and Steele, 1999). 
There is however an argument that an interview technique does add a degree of 
external bias to the questioning, and patients may be reluctant to express their true 
feelings especially when faced with more intimate questions. Self administration is 
therefore widely accepted as being the gold standard method of instrument
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administration. On rare occasions patients may not be physically or mentally capable 
of completing a questionnaire. In these circumstances a proxy respondent can be used, 
for example in patients with terminal illness a close relative who has first hand insight 
into the patient’s everyday quality of life can be recruited (Guyatt et al., 1993; 
Olschewski et al., 1994). Care should be taken in data interpretation from proxy 
respondents; there is evidence both for and against their use. Some authors suggest 
very good correlation of responses between patients and close relatives, particularly 
for functional assessment (Sneeuw et al., 1997; Sneeuw et al., 1998), while others 
have shown significant observer induced bias, inter-observer variation and poor 
correlation in domain assessment other than the physical one (Blazeby et al., 1995; 
Pierre et al., 1998).
The timing of assessment is dependant on the type of disease and on study 
design. In general, a minimum of three assessments are advised, for example the first 
as a baseline before treatment is started, the second during the treatment period and 
third after treatment has finished. Many studies also assess long-term outcome with a 
further assessment some 6-12 months later. With increased frequency of questioning 
there is certainly a higher yield of quality of life data, but cost of implementation and 
complexity of both administration and of data analysis should be considered. Large 
numbers of questionnaires may also have a negative affect on patient compliance. 
Other characteristics to improve compliance include a self administered questionnaire 
taking less than 10 minutes to complete , containing less than 30 questions and being 
easy to understand (Fraser, 1993). The EORTC group published detailed guidelines 
for improving data quality and compliance in clinical trials in 1999 (Young and 
Maher, 1999).
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1.4 Interpretation and clinical application
1.4.1 Introduction
We have described the principle of HRQOL measurement and given some 
information on data collection, but what of interpretation of these results? What is the 
clinical relevance of a particular QOL score and how important are the observed 
changes in patients’ QOL? The scales and instruments used may be poorly understood 
by many clinicians (and patients), and they might reasonably ask how to interpret any 
QOL changes observed. A significant proportion of this comes down to simple 
familiarity with the scales used. Blood pressure (BP) measurement is one of the most 
widely used medical measurements. Both clinicians and patients are familiar with its 
use and understand its principle. The association between elevated BP and increased 
mortality is well recognised, and most clinicians would consider therapy if repeated 
diastolic BP exceeds 100 mmHg. There is however, much less familiarity with the 
scales used in QOL measurement. Hence, the need for information about the level of 
QOL that is to be expected for ill patients and guidelines to help decide what 
magnitude of change makes treatment worthwhile. No single approach is likely to 
provide a complete feel for the meaning of QOL measurements, and thus it is 
important to use a variety of methods for obtaining familiarity.
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1.4.2 Examination of methods
One suggested method of scrutinizing a HRQOL article is to consider it in 3 distinct 
subheadings:
a. Have the investigators measured aspects of health that are important?
The ultimate aim of QOL assessment is to measure the effect treatment has on 
patients’ lives. Having information on HRQOL helps clinicians make informed 
decisions about treatment they provide. In addition to changes in clinical and 
physiological variables, patients expect an improvement in how they feel or how long 
they live. With this in mind, clinicians need to be sure that the QOL research they are 
reading shows a valued effect in patient terms; that is, any measured change in QOL 
will have a significant bearing on how a patient feels or interacts with his or her 
physical and social surroundings. Investigators should show this in their work. They 
may do this by describing in detail the questions that make up their chosen 
instrument. An adequate description of the content of a questionnaire can allow 
clinicians to use their experience to decide if the variables measured, are important to 
patients. Alternatively they may cite articles which show that the instrument used 
measures factors that are of clinical importance to the population studied.
b. Are the measurement properties of the instrument adequate?
The measurement properties of the instrument should be considered. The 
validity, reliability and responsiveness should all be examined. The clinician should 
have at least a basic understanding of these terms before he or she can draw any 
conclusion from results. Clinical papers frequently quote instrument validation and 
responsiveness testing.
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Responsiveness measures how well a questionnaire detects small changes in 
patient status. In clinical trials an unresponsive instrument could give false negative 
results, and fail to detect health improvements after treatment. Care should be taken to 
look at the type of instrument that was chosen. A generic questionnaire used to cover 
each health domain may fail to do so in enough depth to be responsive. Questions 
may be so superficial as to miss even the most important symptom changes related to 
the study. On the other hand, a disease specific or domain specific questionnaire may 
be more appropriate, but likewise this type of questionnaire used out of context of its 
intended target population will be unresponsive.
Validity aims to show that the instrument measures what it intends to measure, 
and not some other factor. Clinicians should look for evidence of validity in the study, 
and in its absence are entitled to scepticism over its measurement of QOL.
c. Are there important aspects of HRQOL that have been omitted?
Investigators may have addressed HRQOL issues, but not done so 
comprehensively. A paper may examine one specific area of outcome but fail to 
consider the broader impact of a disease on patients’ lives. There would be little 
weight to a study, for example, that looked at antidepressant treatment, but failed to 
assess mood or a study may look at a primary area of symptomatology, but fail to 
measure the functional or social impact of a disease. An example could be 
measurement of abdominal pain and bowel function in patients with colorectal 
carcinoma, but failure to examine physical or emotion function. Obviously each case 
should be considered in context, as a more or less exhaustive approach to assessment 
may be appropriate.
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1.4.3 Interpretation of the results
How clinicians should interpret the final results from HRQOL studies is not 
always self evident. For example, patients with acute back pain prescribed bed rest 
had a mean score on the Owestry Back-Disability Index (OBDI), 3.9 points worse 
than controls (Malmivaara et al, 1995). Is this difference trivial, small but important, 
of moderate magnitude, or does it constitute a large and extremely important 
difference between treatments? Investigators can and should help by relating changes 
in HRQOL to well known functional measures, to clinical diagnostic subgroups (e.g. 
change in score needed to move a patient from one subgroup of disease to another), to 
the impact those changes have on daily life or even how they relate to major life 
events such as family illness, loss of job or bereavement (Testa et al., 1993). Studies 
that relate the observed changes to changes in more familiar or objective measures can 
be easier to interpret. Whatever strategy, if investigators don’t provide some 
indication of how to interpret the changes, either directly through comparison with a 
reference or control population, or by citing previous work, then findings will be of 
limited use to the clinician. It is often more informative to know the proportion of 
patients who achieve small, medium or large gains, rather than simple change in 
QOL.
It should also be noted that statistical significance does not always imply 
clinical significance. Statistical significance tests are concerned solely with examining 
the observed data values, to determine whether differences or changes can be 
attributed to chance and patient variability, or whether there is sufficient evidence to 
claim there is almost certainly a pattern in the data. Highly significant p-values 
indicate little about magnitude of differences, and tell us only that the differences are
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probably real as opposed to chance events. They tell us even less about clinical 
significance of the observed changes. In large clinical trials, sample size means that 
even a small change in QOL will be detected and be found to be highly significant. 
However, despite being highly significant in statistical terms, the observed difference 
in QOL might in fact be so small as to be clinically unimportant. The converse is true 
for small studies; barely significant changes may be exceedingly important in clinical 
terms.
1.4.4 Applying results to patient care
As we mentioned earlier, patients with the same disease often vary markedly 
in the QOL they experience. We used the example of one individual with Crohn’s 
disease who may hold down full-time employment, have an active family and social 
lifestyle, while another patient with the same disease extent and severity may be 
depressed, unemployed and unable to fulfil their role in the home environment. To 
truly assess what impact an improvement of QOL might have for an individual 
patient, the study should examine problem areas similar to those of the patients we 
treat. The clinician should aim to find out what problems their patient is currently 
experiencing, the importance he or she attached to those problems and the value they 
might attach to having them ameliorated. Put in simple terms, this should make us 
reflect on the process of communication. Like any area of clinical research, a clear 
understanding of the condition and the patients we treat, is key to the practical 
application of those results.
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1.4.5 Conclusion
In conclusion, the interpretation of QOL results remains essentially qualitative 
(Payers and Machin, 2000). Clinical significance is subjective and often a matter of 
opinion. The values and beliefs of individual clinicians and patients will differ. Thus 
for a QOL measurement scale, it is unlikely that a single threshold value will be 
universally accepted as a cut-off-point that separates clinically important changes 
from trivial or unimportant ones. It is also likely that patients may consider changes in 
some aspects of QOL to be more important than others. A change of 5 points on one 
scale may be as clinically important as a change of 20 in another. However, many 
investigators are finding that for a variety of scales assessing overall QOL and 






Gallstones are one of the most common surgical problems encountered in 
Western society. In Great Britain post mortem studies have shown a very definite 
increase in prevalence over the last 25 years (Bateson, 2000). This is supported by 
studies from Europe (Acalovschi et al., 1987) and North America. Prevalence in the 
UK is estimated at approximately 20-25% in females and 10-12% in males aged 
between 40 and 60 (Godrey et al., 1984; Heaton et al., 1991; Bates et al., 1992), and 
steadily increases with age. These figures are largely based on necropsy studies, but 
are supported by several large ultrasound based studies from Europe. The Multicentre 
Italian Study of Cholelithiasis (MICOL) examined nearly 33,000 subjects aged 30 to 
69 years, and showed overall gallstones rates of 18.8% in women and 9.5% in men 
(Attili et al., 1995a).
2.2 Postcholecystectomy syndrome
Laparoscopic cholecystectomy is now widely accepted as the ‘gold standard’ 
surgical treatment for gallstones. Figures vary as to the percentage of patients who 
will continue to have persistent symptoms following surgery. The term 
‘postcholecystectomy syndrome’ has been used to describe this condition, although
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the term ‘persistent postcholecystectomy symptoms” is probably more accurate. More 
recently the term “postcholecystectomy pain syndrome” is in vogue. Papers have 
quoted relief rates of between 65 (Peters et al., 1991; Bates et al., 1991; Qureshi et al., 
1993) and near 95% (Wilson and Macintyre, 1993; human et al., 1996) for patients 
having surgery. The large variation may be explained because the characteristics of 
symptoms attributable to gallstones are often poorly defined and inaccurately 
measured, and may be assessed at different time points postoperatively. Words such 
as dyspepsia and flatulence can mean different things to different people, so the 
method of evaluation and patient mix will greatly affect the measured relief rates. 
QOL measurement is an example of how patient assessment could be standardised to 
give more reliable and reproducible results.
In their recent paper Berger et al (Berger et al., 2003), conducted a large meta 
analysis to try and evaluate the effect cholecystectomy had on preoperative abdominal 
symptoms. Using a Medline search from January 1966 to January 2000 and from 
reference checking, they identified 542 articles and abstracts looking at symptoms 
after cholecystectomy. Eligibility screening excluded papers where follow-up was less 
than one year, where patients were less than 18 years old, when patients had an 
extraordinary risk of complications e.g. diabetes mellitus and where comparison could 
not be made between pre and postoperative symptoms. After further quality 
assessment only 23 articles were available for analysis. This large number of excluded 
publications highlights why we have such widely differing relief rates reported.
From the included papers, they showed consistently high relief rates after 
cholecystectomy for ‘biliary pain’, defined as severe pain located in the upper
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abdomen or epigastrium lasting for 15 minutes to 5 hours (Schoenfiled et al., 1988). 
The pooled relief rate from the 10 studies in which it could be assessed was 92% 
(95% confidence interval 86 to 96%). They also showed that those patients treated 
electively did significantly worse than those treated in the acute stages of the disease. 
Relief rates were 72% and 86% respectively. Nine of the studies looked at symptoms 
of dyspepsia. Dyspepsia was defined as three or more of either belching, flatulence, 
nausea, intolerance to fatty food, bloating of the abdomen, epigastric discomfort or 
acid regurgitation. Relief rates were heterogeneous and ranged from 46% (Fenster et 
al., 1995) to 89% (Radecke et al., 1993). Talley et al has previously reported placebo 
response rates of almost 70% in patients with functional dyspepsia (Talley et al., 
1991), which was comparable to the average of the studied papers. We also know that 
upper abdominal pain presenting to the general practitioner, disappears without 
intervention within 1 year in around 70% of patients (Muris et al., 1993). These two 
factors alone could explain the observed differences with these dyspeptic type 
symptoms.
They concluded that the methodological quality of the studies in their review 
was low which would have affected the accuracy of the measurements. They felt that 
in these cohort studies it was difficult to confirm that any improvement in symptoms 
was exclusively as a result of surgery. They did not find any randomised placebo 
controlled trials evaluating the effects of cholecystectomy on preoperative abdominal 
symptoms. This they felt was due to the ethical dilemmas that surrounds sham 
operation (Horng and Miller, 2002). They suggested a proper evaluation of the 
effectiveness of cholecystectomy in terms of symptomatic relief required a
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randomised controlled trial, comparing outcomes in symptomatic gallstone patients 
undergoing either cholecystectomy or simple watchful waiting.
This was carried out in 2002 by a Scandinavian group, who prospectively 
looked at patients with symptomatic gallstones (Vetrhus et al., 2002). They 
recognised that for many years it has been an accepted practice that symptomatic 
gallstones are potentially harmful and should be treated aggressively (Mayo, 1911; 
Ransohoff and Gracie, 1993). Long-term follow-up in several large epidemiological 
studies, have shown that the majority of individuals with gallstones remain 
asymptomatic throughout life (Glambek et al., 1989; Friedman, 1993; Attili et al., 
1995b), and Vetrhus et al therefore questioned whether this aggressive management 
was brought about; more through common practice rather than evidence based 
medicine. They stated that the indication for cholecystectomy in symptomatic patients 
had never properly been addressed. In their study, 338 patients were considered for 
inclusion, but after assessment only 137 of these were randomised to either 
observation or surgery. Of the 156 who were not randomised, 79 (51%) had strong 
personal preference regarding their treatment method. There was a low dropout rate of 
9, and median follow-up was 67 months. Their results showed that of the 69 
randomised to observation, 35 (51%) subsequently underwent cholecystectomy and 
that the cumulative risk of having a cholecystectomy seemed to level off after 
approximately 4 years. This may indicate that symptoms abate over time, and similar 
trends have been noted by others (Friedman, 1993). Since the purpose of their paper 
was to examine the feasibility of observation in patients with symptomatic gallstones, 
they did not look at the rates of persistent symptoms after surgery in detail. They 
concentrated rather on complications rates following surgery (6%) and gallstone
31
related complications in the observational group (4%). They recommended that 
patients should be informed that watchful waiting was a safe option.
In a later publication using data from the same study group (Vetrhus et ah, 
2004), the authors focused on pain and quality of life measurement. They 
unexpectedly found a significant reduction in pain and increase in QOL for both 
groups after 6 months, which was maintained until 60 months, at the end of the study 
period. There was no significant difference between the two. They suggested that 
gallstones may in fact have a more benign course than previously surmised, and this 
may be one possible explanation for their findings. Regarding methodology, they used 
two generic QOL questionnaires in the study, which may not have had sufficient 
responsiveness in this particular disease. Small but important differences in QOL may 
have been completely missed between the two groups. To help in their interpretation, 
and to corroborate some of the findings from the Berger paper (Berger et ai, 2003), it 
would have been useful if the authors had examined and discussed outcome in terms 
of individual symptoms that were affected by surgery, alongside the global QOL 
scores.
One other important paper published after Berger’s review, was an article in 
the World Journal of Surgery (Peterli et ai, 2000) in 2000. They compared the 
prevalence of postcholecystectomy symptoms with open cholecystectomy during the 
pre-laparoscopic era, to those with laparoscopic cholecystectomy 4 years after the 
introduction of the technique. On the one hand they surmised that there may be fewer 
symptoms after the introduction of the laparoscopic technique because of the 
advantages it has in terms of fewer adhesions and scar related problems. On the other,
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they thought that an increase may be measured because of the more liberal use of 
laparoscopic cholecystectomy for functional disorders. The latter was supported by 
papers showing a very definite increase in cholecystectomy rates over the previous 
decade, without a parallel rise in the prevalence of gallstones (Logorreta et al., 1993; 
Steiner et al., 1994). The study was well designed and the techniques used for patient 
assessment were consistent for the two groups despite the 5 year gap between 
recruitment times. Pain was measured using the Visick Score (Visick, 1948), Visick I, 
no symptoms; Visick II, minor symptoms without interference of daily activities; 
Visick III, symptoms not relieved by care and influencing daily activities; Visick IV, 
symptoms not improved or relapse. This graduated type of scale was probably of 
more use than a simple VAS, and was chosen to aid with interpretation of results. A 
detailed history of preoperative symptoms was also recorded which included site and 
character of the pain, gastrointestinal symptoms (e.g. bloating, diarrhoea and 
flatulence) and a history of complications (jaundice, pancreatitis and cholecystitis).
Results showed no significant difference between the two groups in the 
prevalence of abdominal symptoms. One year postoperatively, 90% of patients after 
open and 94% after laparoscopic cholecystectomy had no or minor abdominal 
symptoms. They concluded that the prevalence of post-cholecystectomy symptoms 
did not change with the introduction of the laparoscopic technique. In a similar way to 
Berger et al, they found that following open cholecystectomy, patients with typical 
biliary type pain had a better long term outcome than those with dyspeptic symptoms. 
However, they could not show a similar correlation following the laparoscopic 
technique. As we mentioned earlier, one could speculate that the advantages of 
minimally invasive surgery, compensated for the potential negative affect of an
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increased number of cholecystectomies performed on patients with functional 
disorders.
2.3 Pathophysiology of postcholecystectomy syndrome 
2.3.1 Background
Postcholecystectomy syndrome represents a wide variety of conditions with 
overlapping symptoms and often poses a diagnostic dilemma for surgeons and 
gastroenterologists. To help with management its pathophysiology can be considered 
in terms of structural or functional disease, either within or outside the biliary system. 
Among the most common causes are persistent or recurrent disease within the biliary 
system e.g. retained CBD stones or biliary strictures following surgery. These 
surgically remediable causes are usually identified easily and should be treated 
appropriately. There are other well defined entities to explain ongoing or recurrent 
symptoms which are more unusual, and are often difficult to detect or diagnose with 
certainty. These conditions are discussed below.
To help put them in context, they must first be seen in relation to the 
prevalence of abdominal symptoms among healthy individuals. A large 
epidemiological study carried out in Denmark in 1994 looked at abdominal symptoms 
in the general population (Kay et al., 1994). In an age and sex stratified sample of 
4,581 people, they found that 13% of subjects frequently suffered from dyspeptic 
symptoms and as many as 54% complained occasionally. When they examined 
abdominal pain they found that over a one year period the prevalence was 30-50%, 
with 10% having frequent severe episodes. Most symptoms were not persistent or 
chronic, and there was a large resolution rate of 27-47%. Twice as many women with
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abdominal pain consulted their doctor, and they suffered pain episodes significantly 
more frequently than men, and at a younger age. Remarkably only 15% of men and 
10% of women did not experience any abdominal symptoms within the 12 month 
study period. When we consider only those with severe symptoms, then we can not 
expect a cure rate from any therapy to treat abdominal symptoms of more 85-90%.
2.3.2 Duodenogastric reflux
In 1996 Farsakh et al suggested the role of duodenogastric reflux and bile salt 
induced gastritis after cholecystectomy, as a causative factor in the development of 
postcholecystectomy syndrome (bu Farsakh et al., 1996). In their prospective study 
of 30 patients they compared symptoms, endoscopic findings and gastric bile acid 
levels pre and postoperatively. They found a positive correlation between the severity 
of symptoms in postcholecystectomy syndrome and increased bile salt concentrations. 
Interestingly, all those with typical biliary colic pain had resolution of symptoms after 
surgery, while dyspeptic symptoms only improved in around 40%. 17% of patients 
showed an increase in symptoms after surgery and those with gastric ulcers and 
gastric erosions had a higher mean change in bile salt concentration after surgery. The 
results appear to confirm a positive correlation, however, the numbers were small and 
the authors recommended a larger trial to confirm their findings. They also suggested 
controlled trials to examine the effects of prokinetic drugs and cytoprotective agents 
on the symptoms of postcholecystectomy syndrome. Latterly, papers have suggested 
that Helicobacter Pylori may have a synergistic role in development of gastric 
pathology after cholecystectomy. Zullo et al (Zullo et al., 1998) showed a higher
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incidence of bile reflux, gastric metaplasia and helicobacter infection rates in 
cholecystectomized patients.
There is still considerable debate as to the true nature of gastroduodenal reflux 
and its role in postcholecystectomy patients. Some studies have shown no increase in 
bile reflux after surgery (Manifold et ai, 2000), while others have confirmed 
Farsakh’s initial findings (Fountos et al., 2003). A study by an Egyptian group 
showed evidence of gastroduodenal reflux in biopsy specimens of gastric antral 
mucosa one year after cholecystectomy for gallstones (bdel-Wahab et al., 2000). 
There has been some data published on the use of prokinectics and gastro-protective 
agents as treatment measures. Erythromycin (Fountos et al., 2003), sucralfate and the 
proton pump inhibitor rabeprazole have been shown to be of benefit (Santarelli et al., 
2003).
2.3.3 Cystic duct remnant
As I have mentioned, there are several possible mechanical explanations for 
the development of postcholecystectomy syndrome, one of which is retained bile duct 
stones. A more unusual cause however is from a retained stone or stones within the 
cystic duct stump. A recent paper from an Irish group discussed 4 cases of retained 
cystic duct stones causing postcholecystectomy syndrome (Shaw et ah, 2004). Each 
case was treated surgically with resection of the residual cystic duct stump and all had 
resolution of symptoms. The presence of a cystic duct remnant is defined as a residual 
cystic duct greater then 1 cm in length. Studies have shown that the majority of these 
patients are asymptomatic (Lewicki et al., 1973; Larmi et al., 1975). It has also been
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reported that the cystic duct remnant infrequently causes symptoms in the absence of 
other pathologic conditions in the common duct, primarily stones (Hopkins et al., 
1979; Rogy el al., 1991). The incidence of symptoms from a cystic duct remnant is 
unknown, but with the introduction of laparoscopic cholecystectomy and the policy of 
close gallbladder dissection, this may have resulted in an higher number of reported 
cases. The common practice during laparoscopic cholecystectomy is to ligate the 
cystic duct close to the infundibulum of the gallbladder. This technique minimises the 
risk of damage to the common bile duct, but is likely to result in a longer cystic duct 
remnant being left behind.
Symptoms can occur months or even years after cholecystectomy, and the 
remnant is thought to cause symptoms by harbouring residual stones, by developing 
painful neuromas or by having continued chronic inflammation. In some rare cases, 
they have been associated with enteric fistulae (Woods et al., 1992) and with 
Mirizzi’s syndrome (Sowula and Groele, 1999). In cases where a cystic duct remnant 
is thought to be factor, an MRCP should be considered. It has been shown to be 
superior to USS and ERCP at identifying stones within the cystic duct stump (Rubini 
and Dimonte, 1999; Shaw et al., 2004).
2.3.4 Sphincter of Oddi dysfunction
Sphincter of Oddi dysfunction (SOD) has been highlighted as one other 
possible mechanism for postcholecystectomy pain (Evans et al., 1995; Desautels et 
al., 1999). The sphincter of Oddi is a smooth muscle structure surrounding the distal 
common bile duct (CBD), pancreatic duct and ampulla of Vater. It traverses the
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second part of the duodenum obliquely and is almost entirely situated within its wall 
(Tzovaras and Rowlands, 1998). It functions independently of the duodenal 
musculature and acts to control the delivery of bile and pancreatic secretions. It also 
diverts bile to allow storage in the gallbladder and prevents retrograde reflux of 
duodenal contents (Becker, 1993). Over the last decade there has been a wealth of 
articles published that link SOD with biliary and pancreatic type symptoms. Recently 
it has been classified into two subgroups (Chuttani and Carr-Locke, 1993; Toouli, 
1996). Firstly, sphincter of Oddi stenosis which is a structural abnormality due to 
inflammation or fibrosis. Most common causes include pancreatitis, passage of 
gallstones through the sphincter and surgical trauma. The second type is sphincter of 
Oddi dyskinesia, which is an intermittent functional blockage resulting from spasm or 
hypertrophy of the sphincter muscle. It can be associated with other functional 
disorders of the GI tract including irritable bowel syndrome (IBS) (Evans et al., 
1995). Both types have a raised basal sphincter pressure, but unlike sphincter of Oddi 
stenosis, this can be reversed in dyskinesia by administering smooth muscle relaxants.
Cholecystectomy may reveal symptoms of previously undiagnosed SOD 
because there is no longer a gallbladder present to accommodate volumetric and 
pressure changes within the biliary system (Lisbona, 1992). It has been proposed that 
CBD dilatation after cholecystectomy is a feature of SOD with a high predictive value 
for favourable outcome after sphincterotomy (Venu and Geenen, 1986; Thatcher et 
al., 1987). However this finding is non specific since CBD diameter varies with age 
(Coelho and Wiederkehr, 1996) and is detected in around 4 percent of asymptomatic 
patients after cholecystectomy (Graham et al., 1980). There is some objective 
evidence to support the association between SOD and postcholecystectomy syndrome.
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Morphine induced sphincter of Oddi spasm and increased CBD pressure have been 
shown to induce pain in symptomatic postcholecystectomy patients but not in controls 
(Tanaka et ai, 1985). In another recent prospective series Bozkurt et al showed that 
based on manometry findings, endoscopic sphincterotomy was beneficial in patients 
with biliary pain after cholecystectomy (Bozkurt et al., 1996).
The diagnosis and treatment of SOD is complex and a detailed review is 
outside the remit of this thesis, but patient assessment should be based on a range of 
tests that include USS, endoscopic retrograde cholangiopancreatograophy (ERCP), 
manometry which is considered the ‘gold standard’ (Toouli et al., 1986), and 
provocation studies (Nardi and Acosta, 1966; Belsito et al., 1977; Coelho and 
Wiederkehr. 1996). All procedures on the sphincter should be undertaken with caution 
only after careful investigation and patient selection (Tzovaras and Rowlands, 1998).
2.3.5 Psychological factors and somatisation disorders
Psychological factors may be important in the development of 
postcholecystectomy syndrome. They have already been shown to be common in 
patients with functional digestive disorders (Drossman et al., 1999), and some studies 
have looked at the relationship between psychological status and poor outcome after 
cholecystectomy. Patients with postcholecystectomy syndrome have a higher 
incidence of anxiety (Marker!, 1991) and depression (McMahon et al., 1995), and a 
higher intake of psychotropic medications (human et al., 1996). An Italian group 
(Lorusso et al., 2003) looked at this issue in detail. Consecutive patients referred to 
their hospital for laparoscopic cholecystectomy were assessed for inclusion. They
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were screened for symptoms of dyspepsia, which were not characteristic of typical 
biliary colic or gallstone induced symptoms. They broadly defined dyspepsia based on 
criteria established by an international working team (Barbara et al„ 1989). 
Symptoms were classified as episodic or persistent and referable to the proximal 
gastrointestinal tract (e.g. upper abdominal pain or discomfort, postprandial fullness, 
abdominal bloating, belching, early satiety, anorexia, nausea, vomiting, heartburn and 
regurgitation) or referable to the lower gastrointestinal tract and overlapping with IBS. 
All patients had organic disease other than gallstones excluded. From the 124 patients 
screened. 58 (46.7%) were identified with gallstones and dyspepsia. Prior to surgery, 
and at one year after surgery, psychological and gastrointestinal symptoms were 
assessed using validated questionnaires. They used the Hopkins Symptom Checklist 
(SCL-90-R) (Derogatis, 1983) for psychological evaluation and the Gastrointestinal 
Rating Scale (GSRS) (Svedlund et ai, 1988) for digestive symptoms. Patients who 
did not improve scored significantly higher in all subscales of the SCL-90-R, and in 
the dyspeptic and total scores of the GSRS. Logistic regression analysis was used to 
evaluate the association between baseline psychological factors and outcome after 
surgery. All but two subscales of the SCL-90-R were significant predictors for poor 
outcome after cholecystectomy.
This was the first study of its type to use validated QOL instruments to 
investigate how preoperative psychological factors affected outcome after 
cholecystectomy. Its results confirmed a strong negative association between the two, 
and backed up finding of earlier papers published on the subject (Jorgensen et al., 
1991; Borly et al., 1999). The authors suggested that because the criteria for surgery 
are perhaps insufficiently rigorous, and patients’ expectations of symptom recovery
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are sometimes unrealistic, those patients with gallstones should be carefully evaluated 
before laparoscopic cholecystectomy. They felt that a joint psychological and 
gastrointestinal assessment was required preoperatively in those with gallstones and 
dyspepsia. This highlights why Talley (Talley, 1995) and Lumen (human et ai, 1996) 
caution against cholecystectomy in patients with prominent symptoms of dyspepsia 
and other functional digestive symptoms, even though gallstones are present.
Some believe that the syndrome could form part of a somatisation disorder 
(Stefaniak et ai, 2004). Somatisation is defined as repeated presentation of physical 
symptoms, together with persistent request for medical investigations, in spite of 
negative findings and reassurances by doctors that the symptoms have no physical 
basis (World Health Organisation, 1992). Psychological factors such as rumination 
and social factors such as inadequate social support are thought to contribute to this 
persistence of somatoform pain (Weisberg and Clavel, Jr., 1999). Brosschot and 
Thayer state that worry and rumination contribute to both the onset and prolongation 
of medically unexplained somatoform pain. They speculate that this negative thought 
process of illness may stimulate a feed forward process, where progressively more 
illness cues are perceived despite the absence of somatic pathology (Brosschot and 
Thayer, 2004). It is already widely accepted that social support has a significant 
influence on pain, anxiety and recovery following surgical procedures (Neuling and 
Winefield, 1988; Kulik and Mahler, 1989). In addition. House et al state that more 
socially isolated or less socially integrated individuals are less healthy, 
psychologically and physically (House et ai, 1988).
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Stefaniak et al (House et al., 1988; Stefaniak et al., 2004)hypothesised that 
patients with postcholecystectomy syndrome would report more rumination and less 
social support. They looked at patients undergoing surgical treatment for gallstones. 
From the 212 who completed the study, they found that 20 (12.3%) had persistent 
symptoms after surgery. None showed evidence of demonstrable organic pathology to 
explain this. Using linear regression analysis they could demonstrate that patients with 
ongoing symptoms had a significantly lower level of social support, measured on a 
social support scale adapted from the FACIT index (29.78 v’s 34.94; p<0.001). 
Rumination about themselves also showed higher levels in the symptomatic group, 
but was not shown to be significant. Like Lorusso et al (Lorusso et al., 2003), they 
suggested that examining psychological parameters may be helpful in preoperative 
evaluation and postoperative diagnosis for gallstone patients, especially in those 
dissatisfied with the results of surgery.
2.3 Asymptomatic gallstones
Since the introduction of laparoscopic cholecystectomy, there has been a 
worldwide increase in the number of cholecystectomies performed (Logorreta et al., 
1993; Lam et al., 1996). With improved risk-benefit ratios, this may reflect a lower 
threshold for intervention by surgeons or a higher demand for this minimally invasive 
procedure by patients. It may also be partly due to increased use of routine ultrasound 
scan (USS), for the investigation of abdominal pain. This in turn has led to the 
identification of incidental gallstones in a higher number of patients. Ransohoff et al 
followed up 139 patients identified with incidental gallstones on USS (Ransohoff and 
Gracie, 1993). 15 patients (11%) developed symptoms suggestive of biliary colic over
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the next five years, and only 6 proceeded to cholecystectomy for biliary symptoms. It 
was concluded that USS detected coincidental gallstones were infrequently clinically 
significant.
It is largely accepted that the majority of patients who are symptomatic from 
gallstones should be treated (Ransohoff and Grade, 1993), but there is considerable 
debate as to whether the indication should extend to those who have no symptoms 
(Schwesinger and Diehl, 1996). Epidemiological studies suggest that the natural 
history of asymptomatic gallstones is relatively benign, with the majority of patients 
having no trouble throughout life (Glambek et ah, 1989; Friedman, 1993; Attili et al., 
1995b). Symptoms occur at a rate of approximately 1-4% per year, reaching 20% at 
20 years with fewer complications in later years (Barbara et a/., 1987; Friedman et al., 
1989; Strasberg and Clavien, 1993). Complications are almost always preceded by 
symptoms (Thistle et al., 1984; McSherry et al., 1985; Friedman et al., 1989).
Several studies have tried to use objective measurements to predict the 
progression to symptoms or to severe complications such as cholecystitis, jaundice 
and pancreatitis in asymptomatic gallstone patients. A French group looked at 
measurements such as the number and nature of gallstones, gallbladder wall thickness 
and contractility, and demographic details such as age, sex and co-morbid history. 
They found none of these to be significant predictors of outcome in patients with 
asymptomatic stones (Capron and Franco, 1992).
These Figures lend support to the expectant management of most patients w ith 
coincidental gallstones, and certainly when cost-effective analysis is considered the
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argument is strengthened (Friedman, 1993). There are no prospective randomised 
trials of therapy, either surgical or medical for asymptomatic gallstones. However 
decision analysis models have shown no benefit of prophylactic cholecystectomy. In 
one study, for example, decision analysis was used to compare prophylactic 
cholecystectomy with expectant management in patients with asymptomatic 
gallstones (Ransohoff et al., 1983). Prophylactic cholecystectomy slightly decreased 
survival and was not associated with any appreciable gain in discounted life years. 
This study was performed prior to the introduction of laparoscopic cholecystectomy, 
but based on sensitivity analysis included in the study in it doubtful whether this 
would significantly alter results.
In contrast, a Turkish group recently published a paper that questioned the 
merit of conservative treatment of asymptomatic gallstones (Mentes et al., 2001). In 
the first paper of its kind, they used a QOL instrument to compare outcomes of 
symptomatic and asymptomatic gallstone patients after laparoscopic cholecystectomy. 
They showed a significant improvement in QOL in both the symptomatic 
(113.42±21.9 vs. 80.32±19.1 preoperatively; p<0.05) and asymptomatic group 
(113.30±15.2 vs. 96.37±14.26 preoperatively; p<0.05). Despite a higher mean 
preoperative QOL score, there was still a measurable QOL improvement after surgery 
for the asymptomatic patients. These results challenge those of previous publications, 
and question the benign nature of gallstone disease. The authors suggested that 
gallstones perhaps are not truly ‘silent’, and that insidious symptoms such as bloating, 
fullness or vague dyspepsia are more tolerable to the patient and as a result more 
difficult to measure. Their study showed that after surgery these symptoms can 
improve, and patients have significant QOL improvement. Methods used in previous
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studies may not have been sensitive enough to measure subtle preoperative symptoms, 
or demonstrate small but significant QOL improvement after surgery (Glambek et al., 
1989; Attili et al., 1995b). One criticism however, is that follow-up was only for 4 
months, and the ‘placebo effect’ of surgery could explain many of these findings.
Despite the findings of Mentes et al, it is still largely accepted that 
asymptomatic patients are treated expectantly. There are a number of specific 
circumstances however, where it could be argued that prophylactic cholecystectomy is 
justified in an asymptomatic patient. These can be largely divided into two groups. 
Firstly, those at high risk due to certain co-morbid disease (e.g. diabetes, liver 
cirrhosis, sickle cell disease) and secondly those at risk of developing carcinoma. The 
most widely studied group of patients that apply, are those with diabetes mellitus. 
Landau et al (Landau et al., 1992) found that patients with diabetes had a higher 
incidence of infected bile, gangrenous changes and perforation of the gallbladder. 
They also showed that the mortality rate following surgery for acute cholecystectomy 
was significantly higher (21%vs9%). This and other papers prompted early 
cholecystectomy for diabetic patients (Landau et al., 1992; Schwesinger and Diehl, 
1996; Patino and Quintero, 1998). This has however largely fallen out of favour. 
Evidence has shown that for diabetics the morbidity and mortality rates for biliary 
surgery are comparable to non-diabetics (Aucott et al., 1993; Babineau and Bothe, Jr., 
1995). So it is now largely agreed that the magnitude of risk, and the risks and cost of 
cholecystectomy do not warrant prophylactic cholecystectomy in diabetics with 
asymptomatic gallstones. One study identified 70 patients with gallstones and 
diabetes mellitus (Del et al., 1994). They were followed up for five years; 47(70%) 
were asymptomatic at time zero. During follow-up 10% of asymptomatic patients
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developed biliary colic, and 4% developed gallstone related complications. This is 
similar to that of the general population (Gracie and Ransohoff, 1982; Barbara et al., 
1987). In view of this recent evidence, adult diabetics with silent or incidental 
gallstones should be managed expectantly, and prophylactic surgery is not routinely 
recommended (Aucott et al., 1993; Del et al., 1994; Babineau and Bothe, Jr., 1995).
Gallbladder carcinoma is rare except in certain high risk ethnic groups e.g. 
native American Indians. There is a strong correlation between gallstones and 
gallbladder carcinoma. The risk is approximately four times higher for those with, 
than in those without, gallstones. The risk increases when gallstones are equal to, or 
greater than, 3cm in diameter and in patients with gallbladder polyps larger than 10 
mm (Lowenfels et al., 1989). Despite this association prophylactic cholecystectomy is 
not generally indicated (Gibney, 1990). Since the overall prognosis for gallbladder 
carcinoma is very poor, it is suggested that prophylactic cholecystectomy is carried 
out for silent gallstones in areas where gallbladder carcinoma in prevalent (Bosmans 
et al., 1990; Meshikhes, 2002). A porcelain gallbladder is a pathological condition 
characterised by calcification of the gallbladder wall. It deserves special mention, due 
to the high incidence of associated gallbladder carcinoma (15-25%) (Berk et al., 1973; 
Shimizu et al., 1989). This has led many surgeons to practise prophylactic 
cholecystectomy in this small subgroup of patients.
Finally what of incidental gallstones found at the time of surgery for other 
abdominal conditions? Again management strategies are controversial, but at least 
two studies have tried to answer this question. Both showed a significantly higher 
early (within 6 months) complication rate attributable to gallstones which weren’t
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removed at initial surgery (Thompson et ai, 1984; Saade et al., 1987) .They showed 
that concomitant cholecystectomy added minimal morbidity to the operation, and for 
this reason some authors accept that incidental cholecystectomy is safe during 
gastrointestinal surgery, unless specific contraindications exist (Juhasz et al., 1994).
2.4 Irritable bowel syndrome and gallstones
Functional gastrointestinal disorders (FGID) are defined as “a variable 
combination of chronic or recurrent gastrointestinal symptoms not explained by 
structural or biochemical abnormalities” (Talley et al., 1991). They encompass a wide 
variety of syndromes attributed to dysfunction of the oesophagus, stomach, small and 
large intestine, and biliary tract. A recent multinational consensus document was 
published examining the classification, pathophysiology and treatment options for this 
complex group of disorders (Drossman, 1999). Patients with FGID’s can report a 
wide variety of symptoms. Often conditions coexist and symptoms overlap between 
different anatomical regions of the gastrointestinal tract. Categorising these into 
distinct syndromes or subgroups helps in their diagnosis and treatment (Drossman, 
1999).
Among the two most common FGID’s, are IBS and functional dyspepsia 
(FD). They account for 40-60% of referrals to gastroenterology outpatients (Jones et 
ai, 2000). IBS comprises a group of functional bowel disorders in which abdominal 
discomfort or pain is associated with disordered defaecation or change in bowel habit. 
It affects between 10-20% of the adult population (Drossman et al., 1997; Talley and 
Spiller, 2002) and has a female preponderance. Its incidence is unaffected by race or
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age. Several scoring methods have been developed to aid diagnosis and treatment 
assessment. Firstly, in 1978 the Manning criteria (Manning et al., 1978) and more 
recently, the Rome II criteria (Thompson et al., 1999). These criteria have been drawn 
up as a consensus rather than a rigid set of rules. Many patients with abdominal pain 
and altered bowel habit do not fit these criteria exactly, but would still be classified as 
having a functional disorder.
As mentioned above, there can be considerable overlap of symptoms between 
FGID’s. FD refers to persistent or recurrent pain or discomfort centred in the upper 
abdomen, with the absence of organic disease. Dyspepsia can occur commonly in 
patients with symptoms otherwise compatible with IBS (Dotevall et al., 1982; Talley 
et al., 1992). It is also accepted that patients can have both functional dyspepsia and 
IBS, or have upper abdominal discomfort exclusively related to IBS (Talley et al., 
1999). This overlap can make diagnosis and treatment difficult. The aetiology of these 
conditions is poorly understood. It is unlikely that IBS reflects an intrinsic disease of 
the colon, but rather a central neurological dysfunction which can manifest with 
symptoms in several organ systems. This is supported by its strong association with 
stress and anxiety, and with many patients exhibiting abnormal illness behaviour and 
an increased incidence of somatic complaints (Drossman, 1999; Jones et al., 2000).
It has been reported in the past that patients with IBS have a higher incidence 
of cholecystectomy compared to those without (Fielding. 1977). It is suspected that 
many of these operations are unnecessary, and that surgery is actually performed for 
asymptomatic gallstones. IBS can manifest with upper abdominal symptoms, difficult 
to distinguish from gallstones and patients subsequently undergo surgery that is not
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indicated. In a large epidemiological study, a UK group explored this important area 
(Kennedy and Jones, 2000). Their paper described the prevalence of cholecystectomy 
and IBS in a sample of British adults in Teeside. They recruited almost 4500 patients 
to their study, from six general practice registers in the area. IBS was defined as 
abdominal pain on more than six occasions in the previous year, along with three or 
more of the Manning criteria. Patients were asked to complete a symptoms 
questionnaire that had previously been utilised and then validated (Jones and Lydeard, 
1992). The response rate to the postal survey was 72%, and data was analysed from 
3169 questionnaires (1451 men, 1718 women).
The 12 month prevalence of IBS was 17.2%, with a female to male ratio of 
2.2:1. IBS was more common among younger women, and showed a smaller sex 
difference in the older age groups. Cholecystectomy was also more common in 
women than men (4.1% vs. 1.3%). Of the 549 patients with IBS, 109(20%) had 
consulted their general practitioner regarding at least one IBS symptom in the 
previous two years. There was a gradient in the prevalence of cholecystectomy, which 
was lowest in subjects without IBS (2.4%), higher in those with IBS who had not 
consulted (3.9%), and highest in those with IBS that had consulted (7.5%). 
Substantial differences in health beliefs and psychopathology are known to exist 
between patients with IBS who consult, and those who do not (Kettell et ai, 1992). 
With this in mind, these results are all the more striking. The explanation for this 
increased incidence is not entirely clear from the study, and further research was 
recommended. We could speculate that higher attendance with IBS leads to increased 
referral for specialist opinion, and subsequent surgery. This is undoubtedly a 
significant factor, but is unlikely to be the full explanation for the observed difference.
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Those with IBS, who did not attend, also had a higher cholecystectomy rate compared 
to the normal population. This suggests some other underlying mechanism might also 
be to blame. Possibly altered motility in IBS predisposes to gallstone formation (van 
Erpecum and van Berge-Henegouwen, 1999), or if we consider the mechanisms 
behind FGID’s, there may be background physiological changes to account for 
symptoms in both the gastrointestinal and biliary systems (Kellow et al., 1999).
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Chapter 3
Quality of Life and Gallstones
3.1 Introduction
Despite the large number of routine cholecystectomies carried out in the UK 
each year for gallstones, there is a relative paucity of published material looking at 
QOL following surgery for this benign disease. Hepatobiliary conditions in general 
are lacking good quality research in this area, highlighted by the low number of 
disease specific questionnaires available. In the majority of medical specialities the 
balance of published data is weighted towards patients with malignant disease. In 
general this large group of patients have reduced life expectancy and QOL in the 
terminal phases of life is of high priority and its measurement has been used regularly 
for many years. This trend has meant less focus on quality of life measurement 
following surgery for benign conditions, and outcomes have looked at things such as 
length of hospital stay, complication rates and disease recurrence rates.
3.2 QOL and gallstones in the literature
This observation is true also for gallstones and their surgical treatment. Using 
the keyword search headings “quality of life”, “gallstones”, and “cholecystectomy” on 
Medline from 1966-2005 and from cross referencing; only ten English language 
papers have been published which relate to QOL and gallstones. One paper is the
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validation study for the GIQLI (Eypasch et al., 1995) which will be discussed in detail 
in chapter 5. The remaining 9 papers are summarised in Appendix 1, and are 
discussed in turn below.
There has been an exponential rise in the measurement of QOL in medicine 
recently, and it is not surprising that most of the published papers relating to 
gallbladder disease spans only the last 5 years. One paper however stands out as being 
earlier, and would appear to have been well ahead of its time. A Dutch group (Plaisier 
et al., 1994) published the paper in 1994. It was a small randomised study of 49 
patients and compared the treatment of gallstones by either ESWL or traditional open 
surgery. Lithotripsy is a method of stone fragmentation using ultrasonic waves 
(Sauerbruch et al., 1986; Ertan, 2002). Nowadays it is commonly used for the 
treatment of renal stones, but has lost favour in the management of gallstones due to 
poor stone clearance rates (Sackmann et al., 1991) and recurrent stone formation 
(Sackmann et al, 1994; Pelletier et al., 1995). It was done at a time when 
laparoscopic cholecystectomy was still in its infancy, but becoming popular and 
ESWL was being evaluated as an alternative mode of therapy for those unfit for the 
open procedure.
At the time, Plaisier et al cited the theoretical disadvantages of ESWL over the 
gold standard open surgery as being the main reason why QOL was a suitable 
outcome measure rather than merely stone clearance rates. They felt that any form of 
elective surgery was directed primarily towards improvement of QOL and should be 
the most important aim of intervention. They referenced a British Journal of Surgery 
review paper (Fraser, 1993), suggesting that health status-analysis was particularly
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well suited in the area of minimally invasive surgery. Unlike most other QOL studies 
of that time they used a well validated questionnaire. Early QOL studies in surgery 
and other related fields often relied on simple visual analogue scales or self 
assessment questionnaires that were either not validated, widely used or even 
inappropriate to the intervention being measured. It was around that time that the 
MOS 36-item short-form health survey (SF-36) was published (Ware, Jr. and 
Sherbourne, 1992). It gained popularity and raised the awareness of appropriate QOL 
measurement instruments. It quickly became the benchmark from which all other 
instruments were measured and is still a widely used generic instrument, particularly 
in the gastroenterology literature. For their study they chose a translation of the 
Nottingham Health Profile (NHP) (Hunt et al., 1981; Ware. Jr. and Sherbourne, 1992)
. It was one of the first QOL instruments developed well before the SF-36 in the late 
1970s. It was originally intended for use in epidemiological studies comparing health 
status among populations rather than individuals. It measures six dimensions: physical 
mobility, pain, sleep, energy, social function and emotional reaction. Each of these 
dimensions contain questions requiring a ‘yes’ or ‘no’ answer (dichotomous). If 
questions are answered ‘yes’, the patient’s score will be high which indicates a poor 
QOL. At the time it was one of the few well validated questionnaires and scoring was 
weighted, so that a positive response for each item was multiplied by a factor before 
aggregation. Health gain was defined as a reduction in the median score. As opposed 
to the SF-36, the NHP has limited responsiveness and when used in a clinical setting 
results should be interpreted with caution (McEwen and McKenna, 1996). For this 
reason it could be argued that the SF-36 may have been a more useful instrument to 
use in this type of study, but at that time I suspect a Dutch translation was not 
available.
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The design of the study was good. Patients were asked to complete the NHP 
before and at 3, 6. and 12 months after treatment. This method of repeated questioning 
is often used in QOL measurement to ensure reliable data collection. Rather 
surprisingly they claimed a 96% completion rate for the questionnaires, which is well 
above the 70-75% expected rate for most mail surveys (Quintana et al., 2003a) and 
what I have experienced from my own research. It was initially intended that 160 
patients would be recruited to the study, but after a six month period where no 
patients were consented to randomisation the trial was stopped. In the end they 
included 49 patients, 23 randomised to ESWL and 26 to conventional surgery. The 
low numbers may have in part been explained by their strict inclusion and exclusion 
criteria, but they admitted that the study took place at a time when laparoscopic 
cholecystectomy was becoming popular. They claimed that this fact alone severely 
hampered recruitment. Their results showed a more profound and significant 
improvement in QOL in the open cholecystectomy (17.1% improvement, p=0.003) 
group compared with those that had ESWL (10.5% improvement, p=0.113) 
particularly in pain, energy and emotional reaction. They concluded that the NHP was 
a useful tool in general surgery even when the numbers were small. They also 
concluded that in terms of QOL improvement, open surgery was preferred to ESWL, 
particularly when laparoscopic cholecystectomy was not feasible. In those unwilling 
or unfit for surgery they stated that ESWL was an adequate form of treatment because 
most patients have a measured QOL improvement. As discussed previously, they may 
have been able to show a more significant change in QOL following ESWL if they 
had chosen the SF-36 as the main instrument.
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Almost 7 years later a Portuguese group revisited QOL measurement in 
patients undergoing ESWL (Carrilho-Ribeiro et al., 2002). The aim of their study 
was to compare QOL in patients who had previously successful ESWL and who had 
no sign of recurrent stones, to a group of matched patients treated at the same time 
with ESWL but who eventually underwent cholecystectomy for treatment failure. 
From the outset, in terms of QOL measurement their study design was poor. Firstly 
they only took a snapshot measurement of QOL using the now well validated GIQLI 
(Eypasch et al., 1995). The GIQLI is a disease specific questionnaire concentrating on 
mainly digestive type symptoms. It consists of 36 questions each scored from 0 to 4, 
giving a maximum of 144 points. Healthy controls have been shown to score a mean 
of around 120 to 130. Taking only one measurement at a protracted period from 
intervention (in some cases up to 8 years) limits the way their results should be 
interpreted. Health related quality of life (HRQOL) is a dynamic psychological 
variable that can vary from day to day, and be influenced by factors such as additional 
illness that may develop later or even personal problems or socio-cultural events that 
can not be controlled by researchers. It makes no sense to record QOL such a long 
time after intervention when these factors cannot be accounted for. In order to obtain 
reliable data, measurements should have been taken at regular intervals following 
treatment. In addition there was no random assignment, so pre-treatment QOL should 
have been taken to control for possible differences in pre-treatment levels.
Secondly, questionnaires were completed by the main author using telephone 
interview. Telephone interview is generally regarded as a poor technique for data 
collection. Patients may feel less at ease to answer the questions honestly and they 
may also feel they have to ‘say the right thing’, particularly when the interviewer is
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their primary physician. This method therefore raises the question of bias. The third 
criticism of the study is that their numbers were small, with only 18 patients in each 
group. As mentioned above, they were not randomised and the only difference 
between the groups was that those who underwent cholecystectomy had a failure of 
ESWL. The authors admitted that a bias in favour of those successfully treated with 
ESWL could not be ruled out.
Despite their results showing no significant difference in either total QOL 
scores for both groups (128 ESWL vs. 124 Surgery / p=0.33) nor in any of the sub- 
domains, they claimed that the ESWL group had a better QOL when the 8 questions 
examining dyspepsia were examined in isolation. As you would expect their 
conclusions were vague, stating there might be a higher rate of long-term dyspepsia 
with gallbladder preserving treatments. A prospective randomised study using QOL to 
compare gallbladder conserving treatment such as ESWL and laparoscopic 
cholecystectomy was never performed.
Plaisier et al published another QOL paper in 1995 (Plaisier et al., 1995), 
where they prospectively measured QOL in patients after laparoscopic and open 
cholecystectomy. The follow-up period was for one year and was started at a time 
when the benefits of laparoscopic over open cholecystectomy were being studied. 
They again used the NHP for QOL assessment, and with a combination of postal 
questionnaires and telephone surveys, they managed a 96.5% return rate. However, 
their recruitment numbers were small (14 in the laparoscopic group and 17 in the open 
group). They were able to demonstrate a similar significant improvement in QOL in 
both groups after surgery, which reached its maximum earlier in the laparoscopic
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group. They concluded that this was more circumstantial evidence that laparoscopic 
cholecystectomy was superior to open surgery.
In 2002 a Turkish group also published a paper comparing long-term QOL 
after laparoscopic and open cholecystectomy (Topcu et al., 2003). They had large 
numbers of patients in each group and used the SF-36 and GIQTI for QOL 
measurement. The use of two instruments is a well recognised method of 
strengthening data collection and improving sensitivity. It is particularly valuable 
when the criterion validity of one questionnaire is being checked against another 
(usually the ‘gold standard’ index). In this case both questionnaires were already well 
validated at the time of the study and the authors’ aim was to increase sensitivity by 
using both a generic (SF-36) and disease specific (GIQLI) questionnaire. The aim of 
their study was to identify any difference in QOL between the two groups and to use 
QOL as a factor for determining the ‘gold standard’ therapeutic modality for 
cholelithiasis. They pointed out that at that time, laparoscopic cholecystectomy was 
already widely accepted as the ‘gold standard’ treatment supported by published 
morbidity and mortality rates, and data which consistently reported benefits over open 
surgery including reduced post-operative pain, shorter hospital stay, better cosmetic 
results , more rapid recovery and immunological benefits during the early post­
operative period (Soper et al., 1992; Troidl et al., 1992; McMahon et al., 1994; 
Hackam and Rotstein, 1998). There were, however, no published QOL studies 
supporting this, and they felt that QOL was an important criterion that could strongly 
influence the patient’s and surgeon’s choice of operation.
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Unfortunately their method and timing of administration of the questionnaires 
were poor, and were heavily criticised in later publications (Lachinski et al., 2004). 
Similar to the Portuguese group, they failed to randomise patients or to check pre­
operative QOL scores as a baseline, and they only checked QOL at one time point 
with a mean of 41 to 56 months after the primary procedure. Surprisingly, they 
showed a significant difference in all domains of the SF-36 in favour of laparoscopic 
surgery. In terms of symptomatic improvement as measured by the GIQLI, there was 
no overall advantage between the two techniques. As mentioned, the paper was 
heavily criticised (Lachinski et al., 2004). Firstly, and probably rather unfairly, 
Lachinski et al questioned the merit of measuring QOL in patients with gallstones. 
They said that although fashionable at the time, QOL was probably not the most 
appropriate psychological parameter for differentiation between two groups of 
patients suffering from a medical problem that is not likely to have a profound affect 
on QOL. Although QOL was especially important for chronic conditions 
(Makarewicz et al, 2003; Kalso et al., 2003), they claimed that its use in acute 
conditions was moderate at best. Certainly, from the most recent publications on the 
QOL and gallstones (Mentes et al., 2001; Quintana et al., 2003a; Vetrhus et al., 
2004), and indeed from my own results, there is a very definite and measurable QOL 
change after surgery for gallstones which is independent of an acute attack. The most 
likely reason for not having a measurable change in QOL is because the instrument 
used was not sensitive enough. In this example, Topcu et al used the GIQLI which 
has been shown to be sensitive in benign gallbladder disease. Admittedly, they failed 
to use the whole questionnaire, and only administered a cut down version which 
related only to gastrointestinal symptoms. This may have affected the overall 
reliability of the index. Lachinski quite rightly felt that QOL, independent of the
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operative technique, was unlikely to be affected significantly in the postoperative 
course after cholecystectomy, particularly with such a protracted time from surgery. 
Secondly, they criticised the lack of preoperative questioning and lack of 
randomisation, and warned that these methodological drawbacks compromised the 
scientific value of the paper. Their explanation for a measurable difference in QOL 
observed in the study was due to these design faults, and that changes simply reflected 
pre-treatment differences.
In a recent paper from Norway (Vetrhus et ai, 2004), Vetrhus et al compared 
long term QOL between patients undergoing cholecystectomy and those being treated 
with simple observation. As discussed in detail in the previous chapter, the 
conservative approach to gallstone management has been extensively studied in terms 
of symptom free intervals, frequency of recurrent attacks and most importantly the 
incidence of new complications such as jaundice, pancreatitis and gallbladder 
carcinoma. This was an important land-mark paper that compared QOL outcome 
between these two groups. Their aim was to examine frequency and intensity of pain 
attacks and QOL in patients with symptomatic, uncomplicated gallstones treated with 
cholecystectomy or observation.
Compared to previous papers (Carrilho-Ribeiro et al., 2002; Topcu et al., 
2003), their study design and technique of QOL measurement was good. The study 
size was reasonable. From 338 patients considered for inclusion, 137 were 
prospectively randomised to the study (Observation n^OO / Cholecystectomy n=68). 
QOL was measured at time 0, and at 6, 12 and 60 months using the NHP and the 
Psychological General Well Being Index (PGWB) (Dupuy, 1984). The PGWB is a
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well validated (Wiklund and Karlberg, 1991) generic instrument similar to SF-36. It 
consists of 22 questions divided into 6 domains (anxiety, depressed mood, positive 
well-being, self-control, general health and vitality). All items are scored using a 6 
point Likert scale, giving a maximum score of 132. Higher scores indicate positive 
well-being. Interestingly, pain was assessed separately using their own pain score and 
a VAS. They calculated pain as the sum of responses from 4 items related to gallstone 
pain (intensity of pain last week, duration of pain last week, frequency of pain in the 
last 6 months and use of analgesics in the past 6 months). All items were scored using 
a 5 step Likert scale (0-4), giving a range of 0 to 16. Higher scores indicated more 
frequent and severe attacks. The VAS represented the intensity of pain during the last 
week.
Despite being a well designed study, their results were disappointing and 
difficult to interpret. The NHP showed no significant variation over time between the 
two groups. The PGWB however did show a significant improvement in QOL at 6 
months, but this observed variation was the same in the two randomised groups. The 
pain scores also improved with time (maximal at 6 months), but again with no 
difference between the groups. The authors did not expect this finding and made 
several suggestions as to why this trend may have been observed. Firstly, they 
suggested that at the time of recruitment, patients were invariably at a higher level of 
disease activity. Therefore regression towards the mean may be a reason for this 
change in pain and QOL. Secondly, they raised the question about the natural course 
of symptomatic gallstones. They theorised that gallstones may in fact have a more 
benign natural course than previously surmised. Lastly, they questioned the 
sensitivity of their measuring instruments, which I think is the most likely explanation
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for the unusual results. Both the NHP and the PGWB are generic instruments that 
may not be sensitive enough to pick up minor changes in QOL (Jenkinson et al., 
1988) when patients are in a quiescent phase of their disease, a disease specific 
questionnaire would have been preferable. They mentioned the Gallstone Impact 
Checklist (GIC) (Russell et al, 1996) but stated that it had not been extensively 
validated or available to them at the time of their study. The results from the pain 
scores may also be explained by insensitivity in their non-validated questionnaire. 
Interestingly however, they did show that patients in the observed group, who had a 
gallstone related event (e.g. admission due to acute attack or gallstone related 
complications), had significantly higher pain scores than those who did not.
Mentes et al used QOL to compare symptomatic and asymptomatic 
cholelithiasis before and after laparoscopic cholecystectomy (Mentes et al., 2001). 
This was an important study which could answer the question raised by other authors, 
can QOL changes can be measured in asymptomatic gallstones (Vetrhus et al., 2004; 
Lachinski et al., 2004)? Using strict inclusion and exclusion criteria 67 patients with 
gallstones were prospectively recruited, and subsequently underwent uncomplicated 
laparoscopic cholecystectomy. Preoperatively, patients were divided into two groups, 
symptomatic and asymptomatic. Those deemed symptomatic showed the classical 
symptoms of cholelithiasis, that is biliary colic. Patients with complications 
secondary to their gallstones were not included. All patients had gallstones confirmed 
with ultrasound, and QOL was measured using the GIQLI preoperatively and at 4 
months postoperatively. Their results showed a significant increase in the total GIQLI 
score in both the symptomatic (113.42±21.9 vs. 80.32±19.1 preoperatively; p<0.05) 
and asymptomatic group (113.30±15.2 vs. 96.37±14.26 preoperatively; p<0.05). Both
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groups also showed significant improvement in all sub-domains of the index except 
social items which only showed improvement in the symptomatic group. This 
evidence certainly gives positive weight towards the use of the GIQLI for the 
measurement of QOL in gallstones patients. Perhaps more importantly, it added some 
very useful data to support the argument of a more aggressive surgical approach to the 
management of asymptomatic gallstones. It is certainly the only QOL paper showing 
improvement after laparoscopic cholecystectomy for patients with asymptomatic 
gallstones. It is easy to understand how patients with recurrent attacks of severe 
biliary colic will improve, but this evidence suggested that a more indolent or chronic 
course might globally influence well-being. They stated that asymptomatic gallstones 
may not in fact be a truly ‘silent’ disease, and that patients may be more tolerable of 
vague abdominal symptoms, especially if they developed gradually, in parallel with 
chronic gallstone disease. Their follow-up however was only for 4 months, and it 
could be argued that by showing an improvement in asymptomatic patients, they were 
simply demonstrating a ‘placebo effect’ from the surgery.
In 2002 a Danish group published an article in the Lancet where they used 
QOL as a secondary outcome measure to prospectively compare a wait-and-see policy 
or laparoscopic cholecystectomy after endoscopic sphincterotomy for bile duct stones 
(Boerma et al., 2002). They recruited 120 patients to the study, and showed that 47% 
of patients randomised to a wait-and see policy had recurrent symptoms compared to 
2% of the laparoscopic cholecystectomy group. Their use of QOL measurement was 
poorly planned and is open to several criticisms. They used a questionnaire called the 
MOS-Short Form General Health Survey (SF-24) (Stewart et al., 1988), which is a 
generic questionnaire derived from the SF-36 (Ware, Jr. and Sherbourne, 1992). As
62
discussed already, unless combined with a disease specific instrument such as the 
GIQLI, this type of questionnaire is unlikely to be responsive enough, particularly in 
the quiescent phase of this benign disease. Their methods of administration were also 
questionable. Like the Topcu paper (Topcu et al., 2003), they took a single snapshot 
of QOL 3 months after the intervention, and failed to take into account variations in 
preoperative QOL. They introduced controls to the study by comparing QOL in a 
random age and sex matched population, but surprisingly they used the SF-36 for 
QOL measurement. Although this questionnaire is obviously similar to the SF-24, 
there are differences and it is unlikely that data from each is directly comparable. Not 
surprisingly, they found QOL was unhelpful in the selection of treatment strategy, and 
I feel this part of their study was poorly thought out and probably just an added extra, 
since QOL measurement at that time was very popular.
Lorusso et al (Lorusso et al., 2003) used QOL to investigate whether 
psychological symptoms were associated with poor outcome after cholecystectomy, 
which was discussed in detail in chapter 2. They used the SCL-90-R and the GSRS 
for analysis and showed that patients with gallstone disease and dyspepsia were 
unlikely to improve 1 year after surgery if they show psychological distress 
preoperatively.
The final paper that makes up this series was published recently in the British 
Journal of Surgery (Quintana et al., 2003a). It is innovative in its approach to QOL 
measurement, in that is uses data to identify clinical variables that could be used to 
predict outcome following laparoscopic cholecystectomy. They prospectively 
recruited patients to this observational study, and measured QOL using the GIQLI and
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SF-36 before and after surgery. With some 698 patients matching the inclusion 
criteria, and successfully completing the questionnaires, this certainly is the largest 
group of gallstone patients to be recruited to a QOL study. Their method of 
questionnaire administration was sound, and to maximise response to this postal 
survey, they contacted non responders on no less that three occasions. Their final 
uptake rate was a healthy 78.7%. Their data analysis was complex using a 
multivariate linear regression analysis with improvement in QOL as the dependant 
variable. Similar to the Mentes study they subdivided the patient group, this time into 
6 distinct categories. Patients were first classed as either asymptomatic (10.9%), 
symptomatic but with uncomplicated gallstones (62.3%) or lastly, symptomatic but 
with complicated gallstones e.g. pancreatitis, cholangitis or acute cholecystitis 
(26.8%). These three sub groups were further divided into either low (81.6%) or high 
risk (18.4%) based on American Society of Anaesthesiologists scores (ASA). This 
gave a total of six distinct groups of patients. Like Mentes et a! (Mentes et al., 2001) 
they found that patients with symptomatic cholelithiasis had the greatest 
improvements in QOL, especially those with low surgical risk. This improvement 
when compared to asymptomatic patients remained even after adjustment for co­
morbidity and sociodemographic conditions. Asymptomatic patients at high risk were 
chosen as the reference group because conceptually they seemed to be the least suited 
for cholecystectomy and furthermore, in adjusted analysis they were shown to 
experience the least QOL improvement. As one might expect this group was small 
(2.6% of total), which probably reflected the physicians judgement not to operate on 
this type of patient. Compared to this group, those patients with complicated or 
uncomplicated symptomatic cholelithiasis and low surgical risk had greater gains in
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most of the sub-domains of the SF-36 and GIQLI. However statistical significance 
was only reached in the domains of bodily pain and mental health.
They concluded that cholecystectomy was most appropriate for patients at low 
risk, and with the diagnosis of symptomatic stones, especially those with complicated 
cholelithiasis. This matched current recommendations regarding appropriateness of 
cholecystectomy (Johnston and Kaplan, 1993; Johnson, 2001). In contrast to the 
Mentes paper their results supported a conservative approach to the use of 
cholecystectomy for asymptomatic stones, particularly in patients at high surgical 
risk. No previous study had aimed to establish a relationship between patient and 
disease characteristics and QOL improvements after cholecystectomy in patients with 
cholelithiasis.
Shortly after its publication, a short letter in response was printed (Aggarwal 
and Senapati, 2004). It pointed out that the indications for surgery in the 
asymptomatic group, particularly the high risk reference group, should have been 
presented. They stated that prophylactic surgery for asymptomatic gallstones was 
controversial with some favouring expectant management and others selective surgery 
in those at high risk of complications (Schwesinger and Diehl, 1996), and they felt 
that the low QOL gains in this group were self-explanatory. They also commented 
that relief rates in symptomatic patients following cholecystectomy are high in those 
with typical biliary pain, and lower in those with more vague dyspepsia type 
symptoms (Berger et al., 2003) and felt it would have been useful to know the 
distribution of symptoms.
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3.3 QOL and gallstones - what next?
Correlation of QOL change with preoperative symptoms in gallstone patients 






To summarise the discussion in previous chapters, it is apparent that a 
significant proportion of patients undergoing laparoscopic cholecystectomy for 
gallstones experience persistent symptoms after surgery (Peters et ai, 1991: Bates el 
al., 1991; human et al., 1996). Relief rates range from between 65 and 95%, and the 
evidence shows that those who exhibit typical biliary pain have a better outcome than 
those who show atypical dyspeptic type symptoms (Schoenfiled et al., 1988; Radecke 
et al., 1993; Fenster et al., 1995; Berger et al., 2003). The prevalence of persistent 
symptoms does not appear to be affected by the surgical technique employed (Peterli 
et al., 2000). Large Scandinavian and U.S. epidemiological studies have shown that 
the majority of patients with gallstones remain asymptomatic throughout life 
(Glambek et al., 1989; Friedman et al., 1989). It is largely accepted that a 
conservative approach to asymptomatic gallstones should be taken, despite evidence 
showing that laparoscopic cholecystectomy can be performed with minimal risk 
(Coelho et al., 2000).
What of treatment for those with symptomatic gallstones? Symptoms occur at 
a rate of approximately 1-4% per year, reaching a maximum of 20% at 20 years
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(Barbara et al., 1987; Strasberg and Clavien, 1993), and serious complications such as 
pancreatitis, cholecystitis and jaundice are almost always preceded by symptoms 
(Thistle et al., 1984; McSherry et al., 1985; Friedman et al., 1989). Some research 
shows that symptoms abate with time (Friedman, 1993). This was supported by 
Vetrhus et al (Vetrhus et al., 2002) who confirmed in their prospective observational 
study, a low rate of complications (4%) in patients treated expectantly for 
symptomatic stones, and a cumulative risk of needing cholecystectomy that appeared 
to level off after 4 years.
It is known that psychological factors play an important role in developing 
postcholecystectomy syndrome. McMahon et al (McMahon et al., 1995) showed that 
patients who experienced persistent symptoms had a higher incidence of anxiety and 
depression, two factors that have been well documented in association with IBS and 
other FGID’s (Drossman et al., 1999). human et al (human et al., 1996) suggested 
that the subgroup of patients who experienced bloating and altered bowel habit and 
required psychotropic medications may in fact have ‘silent gallstones’ in the 
background of IBS. These types of patients are unlikely to benefit from surgery.
Patients with IBS can manifest with symptoms similar to those of gallstones, 
and higher cholecystectomy rates have been reported (Fielding, 1977). A UK based 
group showed that patients with IBS, particularly those who consult on a frequent 
basis have a higher rate of cholecystectomy compared to the general population 
(Kennedy and Jones, 2000). The exact reason for this increased rate remains unclear. 
Impaired intestinal motility may predispose IBS patients to gallstones (van Erpecum 
and van Berge-Henegouwen, 1999), or they may have some underlying physiological
68
mechanism causing symptoms in both the gastrointestinal and biliary systems (Kellow 
et ai, 1999). Despite these two possible explanations, patients with IBS and other 
functional gastrointestinal conditions undoubtedly undergo unnecessary surgery for 
asymptomatic gallstones.
Measuring HRQOL has become an important endpoint to researchers and 
clinicians and when employed correctly its assessment can help improve quality of 
care. Recently, Quintana et al used QOL to predict outcome in patients following 
laparoscopic cholecystectomy (Quintana et al., 2003a). They showed that those 
patients who were symptomatic and at low risk had the highest health gains after 
surgery. This is the only study to have examined a relationship between preoperative 
disease characteristics and HRQOL improvement after surgery for gallstones. As 
already mentioned, the next logical step is to examine preoperative symptoms in 
gallstone patients and use QOL as a predictor of health improvement.
4.2 Hypothesis
The hypothesis for this study was therefore:
“Patients undergoing laparoscopic cholecystectomy for gallstones do not experience 




The aims of this study were:
1. To show that those patients with proven gallstones who express typical features of 
irritable bowel syndrome preoperatively do not experience a significant 
improvement in quality of life after laparoscopic cholecystectomy.
2. To use quality of life assessment to identify, preoperatively, a subgroup of patients 








As discussed in detail in the first chapter, selection of the correct instrument is 
a crucial step in designing a QOL study. Certain key elements should be considered if 
meaningful results are to be obtained. Factors such as target population or disease 
group, type of instrument, psychometric properties and feasibility of administration 
should all be considered when choosing an instrument (Guyatt et ai, 1993; Moyer 
and Fendrick, 1998).
5.2 Background
In this study the plan was to examine how QOL was affected after treatment of 
gallstones by laparoscopic cholecystectomy. It was felt more appropriate to select a 
disease specific rather than a generic questionnaire, since the primary concern was to 
measure effects on outcome, and to examine how QOL could be used in treatment 
prediction. It was also hypothesised that a significant proportion of the patients would 
be affected by symptoms of IBS, which would be detected more readily if a disease 
specific questionnaire was used. Generic instruments have been used before in 
patients with cholelithiasis (Plaisier et al., 1994; Vetrhus et ai, 2004). In both these 
examples criticisms were made about instrument selection. If a disease specific
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questionnaire had been chosen, particularly in the Norwegian paper (Vetrhus et al., 
2004), more useful information might have been recorded. Disease specific 
questionnaires tend to be more responsive or sensitive to small changes in a patient’s 
clinical state and they can pick up QOL variations even in patients who are in a 
quiesant phase of disease.
5.3 The Gallstone Impact Checklist
Firstly, disease specific questionnaires for gallstones were examined. 
Surprisingly, available QOL data and instruments are lacking for benign hepatobiliary 
disease, in particular gallstones. There was only one questionnaire published at the 
time of study design, the ‘Gallstone Impact Checklist (GIC)’ (Russell et al., 1996). 
This was published in 1996 and has never been widely accepted or validated. The 
questionnaire consists of 41 self administered items encompassing 4 sub-domains: 
food and eating, dyspepsia, emotional impact score and pain sub-score. Using the 
forward search facility on the ISI web of science internet site, this questionnaire has 
only been cited 5 times since its publication (Quintana et al., 2003a; Quintana et al., 
2003b; Vetrhus et al., 2004; McColl, 2004; Quintana et al., 2005). Each time it was 
referenced as a disease specific questionnaire available for gallstones, but as one not 
widely accepted or validated. There were no other published papers that use the GIC 
as their primary instrument, and it was not listed on the PROQOLID website. This 
meant that obtaining appropriate copies, translations, scoring guidelines and databases 
would be difficult. The main reason however for rejecting this questionnaire for the 
study was its lack of validation. It may have been feasible to use it in parallel with
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another questionnaire to give criterion validity, but for reasons stated below this was
also declined.
5.4 Instruments used in IBS
Since there were no suitable instruments to look specifically at patients with 
symptoms from gallstones, focus was turned towards a system specific instrument, 
ideally one that covered symptoms across a number of gastrointestinal conditions. 
This could be expected to measure QOL in patients with gallstones, IBS and 
functional gastrointestinal disorders all of which were important in the design. An 
instrument with a core set of questions and additional modules for specific 
gastrointestinal complaints would have been best, but again no such instrument was 
available. Using one of the already well established generic instruments (e.g. SF36 or 
NHP) in parallel with one or even two other disease specific instruments was 
considered. As discussed above, the GIC could have been used in conjunction with a 
disease specific questionnaire for IBS, for example the ‘Irritable Bowel Syndrome - 
Quality of Life’ (IBS-QOL) (Patrick et al., 1998) or the ‘Quality of Life 
Questionnaire for Functional Digestive Disorders’ (FDDQL) (Chassany et al, 1999). 
The FDDQL in particular stood out as a possible candidate. It was developed in 1999, 
as a single disease specific questionnaire suitable for the measurement of HRQOL in 
IBS and FD. It comprises 43 items that cover areas of daily activity, anxiety, diet, 
sleep, discomfort, coping and control of disease. Its validity and reliability were 
established in an international cross sectional study of 401 patients with IBS and FD 
(Chassany et al., 1999) where it correlated well with the SF-36. It was unclear 
whether the FDDQOL would be suitably responsive to detect symptom improvement
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in patients following laparoscopic cholecystectomy since it had never been used in the 
context of gallstones or post-cholecystectomy syndrome. To ensure suitable symptom 
coverage would mean using the FDDQOL alongside the GIC. A generic instrument 
such as the SF-36 would also be needed for validation of the GIC. This gave a total of 
three instruments consisting of 120 items that would take approximately 40 minutes to 
complete by patients. Several of the questions overlapped or were very similar 
between questionnaires. This, alongside the obvious burden of time placed on the 
patient, could significantly affect compliance, and to expect patients to complete all 
three questionnaires on at least 4 separate occasions was unrealistic. Interpretation of 
three questionnaires would also be difficult, especially when one questionnaire 
remained largely unvalidated.
5.5 The Gastrointestinal Quality of Life Index
Attention turned to look for a single questionnaire that was already validated, 
and had enough responsiveness for use across multiple gastrointestinal conditions. At 
the time only one questionnaire was available to measure HRQOL across multiple 
gastrointestinal disorders, the Gastrointestinal Quality of Life Index (GIQLI) 
(Eypasch et al., 1995). The questionnaire contains 36 items, scored on a five point 
Likert scale from 0-4, giving a total score from between 0 and 144 (Appendix 2). 
Higher scores measure a more favourable response and report a higher QOL. In 
contrast with the GIC, this questionnaire had been extensively validated (Eypasch el 
al., 1995; Nieveen van Dijkum et al., 2000) , and was being used routinely in clinical 
research across different gastrointestinal conditions (Sailer et al., 1998; Slim et al., 
2000; Mentes et al., 2001; Freys et al., 2001; Granderath et al., 2002). Interestingly,
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the authors originally planned to have a set of core questions applicable to any patient 
with gastrointestinal disease along with several small organ specific modules. 
Through their three phase development however, they decided on a single 
questionnaire which could be subdivided into 5 subscales: core symptoms, physical 
items, psychological items, social items and disease specific items. In phase II of 
development, construct validity was supported by demonstrating correlation with a 
global index, the ‘Spitzer Quality of Life Index’ (SQLI) (Spitzer et ai, 1981; Troidl et 
ai, 1987), and a disease specific scale, the ‘Bradburn Affect Balance Scale’ (BABS) 
(Bradburn and Noll, 1969) that measures emotional well-being. During phase III, they 
showed good test re-test reliability with an interclass correlation coefficient of 0.92 
when the questionnaire was applied to 25 clinically stable patients at two time points 
48 hours apart. It also showed excellent internal consistency measured by 
Chronbach’s Alpha (>0.90). During responsiveness testing, they chose patients 
undergoing laparoscopic cholecystectomy for biliary colic as their study group. In 194 
patients who underwent laparoscopic cholecystectomy, a significant improvement was 
observed from a mean score pre-operatively of 87.3 to 111.7 six weeks 
postoperatively (PO.OOOl), showing that this questionnaire was sufficiently 
responsive for use in patients with cholelithiasis. This made the GIQLI particularly 
appealing for use in this study.
5.5.1 The GIQLI and gallstones
Following its publication, it has been used in several studies to examine QOL 
in patients with gallstones; these were discussed in detail in chapter 3. A Spanish 
group published an article using the GIQLI as a predictor of outcome in patients
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grouped according to their anaesthetic risk (Quintana et al., 2003a). In another article, 
Mentes et al looked at QOL following laparoscopic cholecystectomy for symptomatic 
and asymptomatic gallstones (Mentes et al., 2001), and showed that the GIQLI has 
sufficient responsiveness to detect changes in health status following surgery for not 
only symptomatic, but also asymptomatic stones. Finally, after a recent consensus 
conference Korolija et al recommend the GIQLI as the primary HRQOL assessment 
tool for use in gallbladder disease (Korolija et al., 2004).
5.5.2 The GIQLI and IBS
The GIQLI has been used in at least one study of patients with IBS (Coffin et 
al., 2004). They measured QOL in 858 patients with IBS, and found significant 
correlation between symptom intensity and change in QOL. QOL measurement in 
IBS patients is not a new practice, and it isn’t surprising that this index has not been 
used more frequently because four disease specific questionnaires are available for the 
condition (Hahn et al., 1997a; Patrick et al., 1998; Wong et al., 1998; Chassany et al., 
1999). The questionnaire has also been used in a broad spectrum of gastrointestinal 
disorders, such as perforated peptic ulcer (Joneja et al., 2004), gastric bypass surgery 
(Lee et al., 2004b), anal incontinence and constipation (Damon et al., 2004), gastro- 
oesophageal reflux (Granderath et al., 2002; Kamolz et al., 2003) and chronic 
pancreatitis (Witzigmann et al., 2002).
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5.6 Final selection
The basic criteria for selecting an instrument were listed in chapter one, and 
when considered in relation to this study are all fulfilled. The GIQLI has a significant 
amount of data available concerning its validity, reliability, sensitivity and 
responsiveness. The questionnaire has been used before in the target population and 
indeed, part of its psychometric testing involved gallstone patients. Since the 
questionnaire was to be used in isolation, the length was appropriate and the chance of 
compliance maximised. Finally, the questionnaire was published and validated in an 
appropriate language and sufficient reference data and interpretation guidelines were 
available.
5.6.1 Authors permission
A copy of the questionnaire, user manual and database was downloaded from 
the PROQOLID website, and permission to use the questionnaire was obtained in 
writing directly from the author. Professor Ernst Eypasch, Department of Surgery, 
University of Cologne, Germany.
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Chapter 6
The Preoperative Assessment of IBS
6.1 Introduction
In this study it is important to identify preoperatively patients suffering from 
FGID’s, particularly those with IBS. The diagnosis of IBS and other functional 
disorders is based on symptom evaluation (Mearin et al., 2004b). A multinational 
consensus document was recently published, and classified this diverse group of 
disorders according to anatomic region (Drossman, 1999). They also outlined 
diagnostic criteria for each of the disease groups. Distinguishing between disorders 
can however be difficult. Many of the symptoms of IBS for example overlap those of 
FD (Talley et al., 1999).What can make diagnosis more difficult is that symptom 
types can vary with time and in intensity (Mearin et al., 2004a).
6.2 The Manning criteria
The term IBS was first coined in 1944 by Peters and Bargen (Peters and 
Bargen, 1944). Initially thought of as a disease of exclusion, it soon became clear that 
for clinical and research purposes a more rigid set of diagnostic criteria were needed. 
Bristol researchers subsequently reported a group of six symptoms that could 
discriminate people diagnosed with the disorder from those with documented 
structural bowel disease. These became know as the Manning criteria (Manning et al., 
1978) (Table 1). Since each of these symptoms also occurs with organic disease, in 
isolation they are neither sensitive nor specific indicators of IBS. However, the greater
79
the number of symptoms, the higher the likelihood of having IBS. No 
recommendations were given for a threshold number of symptoms to make a positive 
diagnosis, so subsequent studies used two. three or four symptoms as a definition. The 
Manning criteria were corroborated in a study by Talley et al (Talley et al., 1990), 
where they compared symptoms in groups with IBS, organic disease and non-ulcer 
dyspepsia as well as in healthy controls. A significant incidence of symptoms 
attributed to IBS was noted in all groups, again indicating the lack of specificity of 
these symptoms.
Table 1. The Manning Criteria (Manning et al, 1978)
1. Abdominal pain relieved by defaecation
2. Pain associated with looser stools
3. Pain associated with more frequent stools
4. Sensation of incomplete rectal emptying
5. Passage of mucous
6. Visible abdominal distension
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6.3 The Rome and Rome II criteria
A consensus based approach was adopted in an attempt to standardize the 
assessment criteria for IBS. In 1989 an international group of experts met in Italy at 
the XIII International Congress of Gastroenterology and developed the “Rome 
Criteria” (Thompson et al., 1989; Drossman et al., 1990) (Table 2). This helped 
standardise entry levels into clinical studies and allowed investigators to compare 
their results with confidence. The Rome criteria included the symptoms listed by 
Manning et al, but also specified the chronicity term “continuous or recurrent” to take 
into account the nature of IBS which is persistent and relapsing. It also added more 
symptoms concerning altered defaecation. After some modification (Drossman el al., 
1990), it stated that patients must have one of the pain symptoms present for >3 
months, along with three or more of the altered defaecation patterns for >25% of the 
time. This classification was quite complex, and while suitable for research purposes 
was not easily applicable to clinical practice. For this reason it was again modified 
and simplified in 1999 to the “Rome II Criteria” (Thompson et al., 1999) (Table 3). It 
stated that patients should have 12 weeks of discomfort in the preceding 12 months or 
have two of the pain symptoms present. They recommended that the second group of 
criteria included in Rome I were supportive rather than mandatory, and stated that the 
validity of the symptom criteria was supported by patient studies (Manning et al., 
1978; Thompson, 1997; Longstreth, 1997), by factor analysis on populations 
(Whitehead et al., 1990; Taub et al., 1995), and on long term patient follow-up 
(Harvey et al., 1987).
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Table 2. Comparison of Rome Criteria and Revised Rome Criteria
Rome Criteria Revised Rome Criteria
(Thompson et al., 1989) (Drossman et al, 1990)
Continuous or recurrent symptoms of: Continuous or recurrent symptoms for at 
least 3 months of:
Abdominal pain relieved with 
defaecation or associated with a change 
in frequency or consistency of stool
Abdominal pain or discomfort relieved 
with defaecation or associated with 
change in frequency or consistency of
and/or stool
Disturbed defaecation (two or more of): and*
• Altered stool frequency
• Altered stool form (hard or 
loose/watery)
• Altered stool passage (straining or 
urgency, feeling of incomplete 
evacuation)
• Passage of mucous
An irregular (varying) pattern of 
defecation at least 25% of the time (three 
or more of):
• Altered stool frequency
• Altered stool form (hard or 
loose/watery)
• Altered stool passage (straining or
Usually with urgency, feeling of incomplete 
evacuation)
• Bloating or feeling of abdominal 
distension
• Passage of mucous
• Bloating or abdominal distension
^Comment by the committee that the 
decision to include the pain criterion is to 
be left to the discretion of the 
investigators
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Table 3. The Rome II Criteria (Thompson et al, 1999)
Pain or discomfort for 12 weeks of the previous 12 months associated with two of the 
following three:
• Relief with defaecation
• A change in frequency of stool
• A change in consistency of stool
Symptoms that cumulatively lend support to the diagnosis:
• Abnormal stool frequency (>3 bowel movements per day or <3 bowel 
movements per week)
• Abnormal stool passage (straining, urgency or feeling of incomplete rectal 
emptying)
• Passage of mucous
• Bloating or feeling of abdominal distension
6.4 The prevalence of IBS using different scoring criteria
This evolving diagnostic approach has meant differences in study definitions 
of IBS, making comparison between groups difficult. IBS is clearly one of the most 
frequent explanations for chronic gastrointestinal complaints. True prevalence varies 
from between 3 and 20% depending on the criteria used (Drossman et al., 1993; 
Boyce et al., 2000; Saito et al., 2000). A group from Finland recently assessed the 
prevalence of IBS in a random population of 5000 adults (Hillila and Farkkila, 2004). 
They used both the Manning and the Rome I and II criteria in their assessment, and
83
found that prevalence estimates using three of the Manning criteria were significantly 
higher when compared to either Rome I or Rome II (9.7% vs. 5.6% or 5.1% 
respectively). Interestingly when only two Manning symptoms were used the 
prevalence estimates were much higher (16.2%). This corroborated the findings of 
Saito et aL that the Manning criteria identifies a higher number of patients with IBS 
compared to Rome I (Saito et ai, 2000). They concluded by saying that it was unclear 
whether the Rome I or the Manning definition was the better means of identifying 
patients with IBS, but agreed it was useful to understand the differences between the 
two in order to interpret the literature regarding it. One argument is that the Manning 
criteria are in fact more sensitive at identifying cases than either Rome I or Rome II. 
Hahn et ai went further and postulated that both the Manning criteria and the Rome I 
criteria underestimate the true number of sufferers (Hahn et al., 1997b).
6.5 Choosing a scoring method
So which should be used? It is clear that these criteria were drawn up as a 
consensus rather than a rigid set of rules. In clinical practice the diagnosis of IBS is 
often made by exclusion of organic disease, aided by a lack of “alarm” symptoms 
such as bleeding and weight loss, and on past experience or clinical intuition. Most 
general practitioners have never heard of, or use either the Manning or Rome criteria 
(Thompson et ai, 1997; Agreus, 2000), and studies have shown poor agreement in the 
diagnosis of IBS made by them and those identified by the Rome II criteria (Vandvik 
et al., 2004). It would appear that the Rome definition and Manning criteria are too 
complicated to use in a busy clinical environment. For research purposes however it is
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vitally important that validated diagnostic criteria are implemented, so results can be 
compared with confidence.
Since opinions differ regarding what constitutes the most appropriate 
diagnostic method, and the evidence shows clear differences in population selection 
between those that are available, this study will use IBS symptoms applicable to both 






After deciding on the most appropriate QOL questionnaire (Eypasch et al., 
1995), and on suitable grading criteria for IBS (Manning el al., 1978; Thompson et 
al., 1999) a plan was formulated to examine how HRQOL outcome was affected 
following laparoscopic cholecystectomy. This was to be a prospective observational 
study to measure change in QOL over time and correlate this with preoperative 
symptoms in order to predict outcome. As discussed in chapter one, the technique of 
administration of the questionnaires was considered. It was decided that the GIQL1 
should be completed on at least three separate occasions, once preoperatively and at 6 
and 12 weeks postoperatively. This technique is well recognised for obtaining a more 
accurate representation of QOL change (Langenhoff et al., 2001), but increased 
frequency of questioning can affect compliance (Fraser, 1993). Since only one 
questionnaire was employed with a completion time of less than 10 minutes, it was 
agreed that this would probably not be an issue. A 6 week period after surgery was 
felt to be a sufficient time to recover from the initial surgical insult, and to give a true 
measurement of health change. To further strengthen the data it was later decided to 
include a long term follow-up questionnaire 2 years down the line. For patients unable 
to complete the questionnaire unaided, an interviewer technique or even proxy data
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collection is sometimes instituted (Fletcher et al., 1992). It was felt that this would 
introduce unnecessary bias to results (Guyatt et al., 1993) so these patients were 
excluded from the study.
7.2 Patient recruitment
Patients with proven gallstones on USS who were placed on a routine waiting 
list for laparoscopic cholecystectomy were recruited. Prior approval was sought from 
the regional ethics committee. Patients were recruited from 3 local hospitals. The 
Mater Hospital, The Royal Victoria Hospital and Craigavon Area Hospital. 
Permission to perform the study was obtained from hospital administration as well as 
the consultants in charge of each patient. It was initially planned to prospectively 
recruit all patients at the time of booking during their outpatient appointment. Since a 
significant delay was observed between booking and surgery, patients already on the 
waiting list were also asked to take part at the time of admission for their surgical 
procedure. Verbal consent (Appendix 3) was given and each patient was given an 
information sheet outlining the details of the study (Appendix 4).
At the time of study design there were limited data available on QOL after 
cholecystectomy and its relationship to preoperative symptoms. There were only two 
papers published that used the GIQLI as an index, the original validation paper by 
Eypasch et al (Eypasch et al., 1995) and one by Mentes et al that assessed 
symptomatic and asymptomatic cholelithiasis before and after surgery (Mentes et al., 
2001). Since follow-up questionnaires were to be administered by post, at least a 30% 
drop-out rate was expected. Using figures from the previous studies, a simple power
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calculation showed a sample size of 110 patients would be sufficient to detect a 10 
point change (either increase or decrease) in QOL, and achieve statistical significance 
to the 1% level. It was decided to aim for a study size of 150 to take into account non 
responders and those patients subsequently excluded from the study.
7.3 Inclusion and exclusion criteria
Patients were not included in the study if they fulfilled any of the following criteria:
1. Failure to give verbal consent, or agree to postoperative follow-up.
2. Unable to comprehend or complete the questionnaire e.g. blindness, dementia 
and severe psychiatric illness.
3. Pregnancy.
4. Alcohol or drug abuse.
5. Proven chronic organic disease thought to significantly affect HRQOL status 
e.g. inflammatory bowel disease, diabetes and bronchitis.
Patients were subsequently excluded from the study if they fulfilled any of the 
following criteria:
1. Failure to complete the QOL questionnaire preoperatively along with at least 
one postoperatively.
2. Proven neoplastic disease or gallbladder carcinoma subsequently identified on 
histopathology.
3. If patients had a significant complication during or as a result of surgery, for 
example, bile duct injury, bile leak, retained duct stone or infection.
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7.4 Controls
Since the questionnaire was administered preoperatively and again 
postoperatively to calculate change in QOL, patients acted as their own controls.
7.5 Data Collection
After consent for inclusion patients were asked demographic details and 
questions regarding symptomatology. These were recorded on a detailed pro-forma 
(Appendix 5) which had been designed to include symptoms relevant to both 
cholelithiasis and FGID’s. It was divided into subheadings which included: previous 
investigations, details related to pain or discomfort, cholelithiasis, IBS, symptoms of 
gastroduodenal disorders and brief details of any previous psychiatric illness. There 
was sufficient detail to allow calculation of both the Manning and the Rome II criteria 
for IBS. The pro-forma was designed in a simple tick box format to avoid ambiguity 
and to ensure all relevant details were documented. For certain symptoms that were 
similar in nature, for example fullness or bloating, a brief explanation of the exact 
meaning of each was given to ensure they were accurately recorded. The pro-forma 
was completed by the doctor who booked the patient for surgery or by the person who 
took consent preoperatively for surgery.
Following the pro-forma patients completed the preoperative GIQLI 
questionnaire. The technique of answering the questions was explained and it was 
emphasised that no question should be left blank. To avoid user bias or interference 
they were asked to fill out the questionnaire unaided. It was then collected before the 
patient left the outpatient clinic or went for surgery. At three time points after surgery
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(6 weeks, 3 months and 2 years) patients were again asked to complete the GIQLI. 
This part of the study was carried out as a postal survey. In an attempt to improve 
response rates, questionnaires were sent with covering letters and stamped addressed 
envelopes. Again, to avoid the issue of bias either for or against the operating 
surgeon, the questionnaires and letters were addressed from the Department of 
Surgery, Queens University Belfast, and not from individual hospitals or consultants. 
At each time point, patients who did not reply within 15 days were sent a second letter 
and copy of the questionnaire. If they failed to reply for a second time it was 
presumed they no longer consented to take part in the study and were not contacted 
further. If patients failed to complete at least one questionnaire following surgery they 
were excluded. Three months after initial discharge patient records were reviewed, to 
determine the need for readmission or any significant complication related to or 
following the procedure.
7.6 Statistical methods
Data was entered into the statistical analysis package SPSS ® Version 12 
(SPSS Inc., Chicago, USA). Patients were identified using their unique hospital unit 
number. From the patient pro-forma, symptoms were recorded as being present, 
absent or not recorded and given the values 1, 0 or 99 respectively. Similarly, 
responses to each of the GIQLI questions were recorded from 0 to 4 where 0 was the 
least favourable response and 4 the best response. Again, missing data was recorded 
with a value of 99. Outcome was measured in terms of global QOL scores at 6 weeks, 
3 months and 2 years. Mean postoperative QOL scores and the 4 domain scores of the 
index were calculated. Differences between and within groups were analysed using 
analysis of variance followed by the appropriate paired or independent t-test.
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Symptom and outcome correlation was carried out using stepwise linear regression 
analysis models where mean postoperative QOL was the dependent variable and 
independent variables were an interaction term of the baseline score before surgery. 
Manning symptoms, Rome II criteria and the individual symptoms recorded in the 
patients pro-forma. Summary values are expressed as mean ± SEM and significance 







One hundred and fifty eight patients were enrolled in the study with a mean 
age of fifty three years. Thirty five patients (22.2%) failed to complete at least one 
postoperative questionnaire and were excluded. Five (3.5%) further patients were 
excluded due to significant postoperative complications (2 with bile leaks requiring 
drainage, 2 with retained bile duct stones and 1 with a bowel injury). No patients met 
the exclusion criteria of gallbladder carcinoma diagnosed at histopathology, and there 
were no deaths in the study group. During follow-up two patients were diagnosed 
with a significant organic disease (one with metastatic carcinoma and one with 
inflammatory bowel disease) thought to affect HRQOL and data from these patients 
were not included.
Therefore a total of one hundred and twelve patients (70.9%) had sufficient 
data sets for inclusion. This reached the estimated number required to show 
significance by the previous power calculation. As expected with gallstone disease 
there was a strong female preponderance. There were ninety eight women (87.5%) 
and fourteen men (12.5%) in the study giving a female to male ratio of 7:1. The mean 
ages were 51.5 and 61.4 years respectively. The age range for the group was from 23 
to 81 years. Patients were recruited from three local hospitals, 22 (19.6%) from
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Craigavon Area Hospital, 49 (43.8%) from the Mater Hospital, Belfast and 41 
(36.6%) from the Royal Victoria Hospital, Belfast.
8.2 Comparison of pre and postoperative QOL scores
Patient’s global quality of life scores were calculated for the four time points 
in the study. These will be referred to as Q1 for the preoperative questionnaire and 
Q2, Q3 and Q4 for the postoperative questionnaires taken at 6weeks, 3 months and 2 
years respectively. Mean scores are summarised below in table 4. The mean 
preoperative score was 88.8 ± 1.3 (61.7% of 144, the highest score possible with the 
index) and improved significantly 6 weeks after surgery to 105.5 ± 1.3 (p<0.001). 
This improvement was maintained at 3 months, but at 2 years analysis showed 
significant regression towards the baseline of 7.6 ± 2.3 (p=0.003) points. Mean 
change in QOL is summarised in table 5.
Std. 95% Confidence Interval
Questionnaire Mean Error Lower Upper
Pre-operative (Q1) 88.8 1.3 86.3 91.4
post 6 weeks (Q2) 105.5 1.3 102.9 108.0
post 3 months (Q3) 107.2 1.7 103.8 110.6
post 2 years (Q4) 99.6 1.9 96.0 103.3







95% Confidence Interval 
Lower Upper
Q1 to Q2 16.7 1.8 <0.001 13.0 20.3
Q1 to Q3 18.4 2.2 <0.001 14.1 22.6
Q1 to Q4 10.8 2.3 <0.001 6.3 15.3
Table 5. Mean change in global QOL scores
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3 lo-
Change in QOL Q1 to Q2
Figure 6. Histogram showing change in QOL between preoperative and 6 
week questionnaires
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Mean = 15.4211 
Std. Dev. = 22.02617 
N = 112
Mean Change in QOL
Figure 7. Histogram showing change in QOL between the preoperative 
questionnaire, and the mean score of all three postoperative questionnaires
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8.3 Domain scores
Data for the four sub-domains of the questionnaire were analysed. The 
physical wellbeing domain included questions 15 to 21 of the GIQLI (Appendix 2) 
and had a maximum score of 28. The GI symptoms domain included questions 1 to 9 
and 27 through to the end of the questionnaire; the maximum score for this section 
was 76. The social domain consisted of the 5 questions numbered 22 to 26 with a 
maximum score of 20 and finally the emotions sub domain was made up of the 
remaining questions 10 to 14. again with a high score of 20.
8.3.1 Physical wellbeing
This domain showed significant improvement after surgery. The mean 
preoperative score was 14.1 ± 0.4 and increased by around 12% after 6 weeks to 17.4 
± 0.4 (p<0.001). This change was maintained to 3 months, but there was partial 
regression towards the baseline after 2 years 16.2 ± 0.5 (p=0.002). These figures are 
summarised below.
Std. 95% Confidence Interval
Physical Wellbeing Mean Error Lower Upper
Pre-operative 14.1 0.4 13.4 14.9
Post. 6 weeks 17.4 0.4 16.7 18.2
Post. 3 months 18.0 0.5 17.0 19.0
Post. 2 years 16.2 0.5 15.1 17.2
Table 6. Mean physical wellbeing scores before and after surgery
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Q1 to Q2 3.3 0.5 <0.001 2.2 4.3
Q1 to Q3 3.9 0.6 <0.001 2.7 5.1
Q1 to Q4 2.1 0.7 <0.001 0.8 3.4
Table 7. Mean change in physical wellbeing scores
8.3.2 Gl symptoms
This domain showed significant improvement after surgery. The mean 
preoperative score was 50.5 ±0.7 and increased by 11% after 6 weeks to 58.6 ±0.7
(p<0.001). Unlike the physical domain this improvement in QOL was maintained
through to the end of the study period at 2 years 57.1 ±1.1 (p<0.001).
Std. 95% Confidence Interval
Gl symptoms Mean Error Lower Upper
Pre-operative 50.5 0.7 49.1 52.0
Post. 6 weeks 58.6 0.7 57.1 60.1
Post. 3 months 58.9 1.0 57.0 60.8
Post. 2 years 57.1 1.1 55.0 59.2
Table 8. Mean GI symptoms scores before and after surgery









Q1 to Q2 8.1 1.0 <0.001 6.0 10.1
Q1 to Q3 8.3 1.2 <0.001 6.0 10.8
Q1 to Q4 6.6 1.3 <0.001 4.0 9.1
Table 9. Mean change in GI symptoms scores
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8.3.3 Emotional wellbeing
Emotional wellbeing showed a trend similar to the GI symptoms domain. A
statistically significant improvement was measured after surgery and was maintained
through to 2 years. The mean preoperative score was 11.1 ± 0.3 and increased by
17.5% to 14.6 ± 0.3 (p<0.001) after 6 weeks.
Std. 95% Confidence Interval
Emotional wellbeing Mean Error Lower Upper
Pre-operative 11.1 0.3 10.5 11.6
Post. 6 weeks 14.6 0.3 14.0 15.1
Post. 3 months 15.0 0.3 14.3 15.6
Post. 2 years 14.1 0.4 13.4 14.9
Table 10. Mean emotional wellbeing scores before and after surgery









Q1 to Q2 3.5 0.4 <0.001 2.8 4.2
Q1 to Q3 3.9 0.4 <0.001 3.0 4.7
Q1 to Q4 3.1 0.4 <0.001 2.1 3.9
Table 11. Mean change in emotional wellbeing scores
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8.3.4 Social wellbeing
Social wellbeing also showed significant improvement after 6 weeks which 
was maintained at the 3 month questionnaire. Unlike the other domains however it 
showed full regression back to baseline at the 2 year time point. The mean 
preoperative score was 13.1 ± 0.5 increasing by 8.5% to 14.9 ± 0.3 (p<0.001) 6 weeks 
after surgery and returning io 12.2 ± 0.4 (p-0.05) at 2 years.
Std. 95% Confidence Interval
Social wellbeing Mean Error Lower Upper
Pre-operative 13.1 0.3 12.6 13.6
Post. 6 weeks 14.9 0.3 14.3 15.4
Post. 3 months 15.4 0.3 14.7 16.0
Post. 2 years 12.2 0.4 11.5 13.0
Table 12. Mean social wellbeing scores before and after surgery









Q1 to Q2 1.7 0.4 <0.001 1.0 2.5
Q1 to Q3 2.2 0.4 <0.001 1.4 3.1
Q1 to Q4 0.8 0.5 <0.001 -1.8 0.1
Table 13. Mean change in social wellbeing scores
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post 2 yrspreoperative post 6 wks post 3 mths
Questionnaire Number




post 6 wks post 3 mths
Questionnaire Number
post 2 yrspreoperative
Figure 9. Change in GI Domain Score Following Surgery
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8.4 Comparison of Manning scores with change in QOL
At recruitment 32 patients (28.8%) had 2 or more Manning symptoms present. 
Using stepwise multivariate linear regression analysis. Manning scores were 
correlated with change in QOL. There was a significant negative correlation of -5.2 ± 
1.29 (p<0.001) points between Manning symptoms and QOL scores after surgery.
Figure 10. Box plot showing change in QOL vs. numbers of Manning symptoms
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8.4.1 Comparison of Manning scores with changes in QOL 
domains
Manning symptoms also showed a significant negative correlation across all 
four sub-domains of the questionnaire. The greatest effect was seen in the GI 
symptoms domain, with a 3.9% (-2.98 ± 0.66 p<0.001) lower domain score for each 
symptom present. The other sub-domains showed a similar negative effect, but the 
measured effect on global QOL was less. Figures are summarised in Table 14 below.
QOL Domain
Change in Domain 





% Change in 
Global Score




G/ symptoms -2.98 0.66 -2.1% -3.9% <0.001
Physical -1.30 0.34 -0.9% -4.6% <0.001
Social -0.59 0.22 -0.4% -2.9% <0.001
Emotions -0.72 0.24 -0.5%
J____________
-3.6% <0.001
Table 14. The effect of Manning symptoms on GIQLI sub domain scores after surgery
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8.4.2 Manning symptoms as predictors of outcome
The six individual symptoms that make up the Manning criteria (Table 1) were 
examined to see if any were predictors of outcome. Three out of the six were found to 
be significant. The largest effect was seen in patients who described loose bowel 
movement with the onset of pain. Regression analysis showed that patients with this 
symptom had a -17.3 ± 4.6 (p<0.001) lower global QOL score following surgery 
compared to those who didn’t (Table 15). Abdominal distension was the most 








% Change in 
Global Score P Value
Loose Bowel 
Movement with Pain -17.3 4.6 -11.9% <0.001
More Frequent Bowel 
Movement with Pain -14.9 5.4 -10.3% 0.007
Pain Relief with Bowel 
Movement -14.1 5.3 -9.8% 0.009
Abdominal Distension -6.9 4.1 -4.8% NS
Passage of Mucous -11.1 5.9 -7.7% NS
Incomplete Emptying -11.4 5.7 -7.9% NS












Actual Pain relieved More Looser Mucous Incomplete
abdominal with frequent stools with Emptying
distension defecation stools with onset of pain 
onset of pain
Figure 11. Frequency of Manning Symptoms Recorded
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8.5 Comparison of Rome scores with change in QOL
Rome scores also showed a significant negative correlation with QOL change 
following surgery. As we have discussed, the Rome II criteria (Table 3) are a 
subdivision of the Manning criteria with an added chronicity term. Of the 32 patients 
with 2 or more Manning symptoms present, 21 (19%) also fulfilled the Rome II 
criteria for diagnosis of IBS and had a -12.5 ± 5.0 (p=0.15) lower QOL after surgery 
compared to those who didn’t. When the Rome II criteria were compared to the 
changes in domain scores, they had a significant negative effect on the GI symptoms 
and physical function sub-domains but not the social or emotional domains (Table 
16).
QOL Domain
Change in Domain 





% Change in 
Global Score




GI symptoms -7.41 2.61 -5.1% -9.7% 0.005
Physical -3.54 1.31 -2.5% -12.6% 0.008
Social 0.55 0.77 +0.4% +2.8% NS
Emotions 0.65 0.08 +0.5% +3.2% NS
Table 16. The effect of the Rome II criteria on GIQLI sub domain scores after surgery
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8.6 Comparison of functional Gl symptoms with change in QOL
The functional gastrointestinal symptoms recorded in the pro-forma 
(Appendix 5) including nausea and vomiting were correlated with change in QOL 
after surgery. A feeling of fullness was the only one found to be a significant predictor 
of outcome. There was an 11.1 ± 5.2 (p-0.035) higher QOL score in patients 
describing this symptom. Results of outcome are summarised below (Table 17), and 







% Change in 
Global Score P Value
Feeling of Fullness +11.1 5.2 +7.7% <0.001
Bloating/Tightness +0.2 4.3 +0.1% NS
Heartburn -7.9 4.8 -5.5% NS
Dysphagia -1.6 11.1 -1.1% NS
Early Satiety -2.4 4.8 -1.6% NS
Belching -6.0 4.6 -4.2% NS
Nausea and Vomiting -4.4 5.5 -3.1% NS























Dysphagia Nausea and 
Vomiting
Figure 12. Frequency of Functional GI Symptoms
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8.7 Cholelithiasis and change in QOL
The three variables specific to cholelithiasis were correlated with change in 







% Change in 
Global Score P Value
Previous Abnormal 
Liver Function Tests +2.0 5.2 +1.4% NS
Fat Intolerance +5.8 4.3 +4.0% NS
Previous Gallstone 
Related Complication +3.3 4.8 +2.3% NS
Table 18. The effect of symptoms of cholelithiasis on QOL
40-
3 20-
Previous abnormal Fat intolerance Previous complications
LFT’s
Figure 13. Frequencies of Gallstone Related Variables
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8.8 Psychiatric history
A previous psychiatric history was recorded in 19 patients (17%). All were 
female with 15 describing an ongoing or previous depressive illness, and the 
remaining 4 having anxiety related disease. In terms of outcome this was highly 
significant with a -21.5 ± 5.2 (p<0.001) lower QOL score after surgery compared to 
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The present study was designed to investigate the correlation between 
preoperative symptoms of FGID’s (i.e. IBS) and outcome following laparoscopic 
cholecystectomy for symptomatic gallstones. The primary outcome measurement was 
QOL using the GIQLI. The hypothesis stated that “Patients undergoing laparoscopic 
cholecystectomy for gallstones do not experience significant quality of life 
improvement, if they exhibit typical features of irritable bowel syndrome”.
Postcholecystectomy syndrome is a term used to encompass a diverse variety 
of symptoms that can persist following surgery for gallstones. The quoted relief rates 
vary from 65 to 95% (Bates et al., 1991; human et ai, 1996), and there is evidence to 
show that the surgical technique employed (i.e. open or laparoscopic) does not 
influence long term outcome (Peterli et al., 2000). In a recent meta- analysis Berger et 
al (Berger et al., 2003) showed that patients exhibiting typical biliary pain had higher 
relief rates than those who’s main complaint was dyspepsia (92% vs. 46 to 89% 
respectively).
There are undoubtedly patients whose predominant symptoms are functional, 
yet have surgery for gallstones, human et al (human et al., 1996) warned against
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operating on those who experienced bloating and altered bowel habit and required 
psychotropic medication. They stated that these types of patients were unlikely to 
benefit from surgery, and would be expected to have a higher rate of persistent 
symptoms after cholecystectomy. IBS is one of the functional gastrointestinal 
disorders characterised by abdominal discomfort along with altered defaecation or 
change in bowel habit. The symptoms of IBS commonly overlap those of functional 
dyspepsia (Talley et ai, 1999), and in patients with coexistent gallstones drawing up a 
management plan can be difficult. IBS sufferers are a group that one might expect to 
have a less favourable result following surgery for gallstones. No previous study has 
shown a worse outcome after cholecystectomy in this subgroup. Evidence that surgery 
could be avoided in some IBS patients is supported by population based studies 
showing higher cholecystectomy rates compared to the general population (Fielding, 
1977; Kennedy and Jones, 2000). On the other hand this increased rate of intervention 
may indeed be appropriate. It could be explained by altered colonic motility 
predisposing IBS patients to gallstone formation (van Erpecum and van Berge- 
Henegouwen, 1999) or by an underlying neuro-physiological condition affecting 
smooth muscle contractility in both the gastrointestinal and biliary systems and 
causing symptoms in both these organ systems (Kellow et ai, 1999).
Nevertheless there is clear evidence that in the laparoscopic era the rate of 
cholecystectomy has increased without a parallel increase in the prevalence of 
gallstones. One Scottish group reported an increased surgery rate of up to 25% 
between 1989 and 1993 (Lam et ai, 1996). Numerous studies have shown distinct 
advantages over its open counterpart (Grace et ai, 1991; Macintyre and Wilson, 
1993), and with reduced risk-benefit ratios this higher surgical rate may reflect a
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lower threshold for intervention or a higher demand for ‘key hole’ surgery by patients. 
With over 50,000 laparoscopic cholecystectomies preformed in the UK and Ireland 
each year, this has major cost implications. If we could predict patients who were less 
likely to benefit from surgery and treat them expectantly, there would be financial 
gains and benefits in terms of patient health from reduced morbidity by unnecessary 
surgery.
9.2 Summary of results and discussion
9.2.1 Recruited patients
From the one hundred and fifty eight patients initially recruited to the study 
thirty five (22.2%) failed to complete at least one of the postoperative questionnaires. 
Data from these patients could not be included in the study. This matched the 
expected drop out rate predicted at the time of the power calculation, and was similar 
to other studies where follow-up by postal survey has been utilised (Kennedy and 
Jones, 2000; Quintana et al., 2003a). 111 (99.1% of included subjects) completed the 
6 week questionnaire (Q2), 73 (65.2% of included subjects) completed the 3 month 
questionnaire (Q3) and 64 (57.2% of included subjects) completed the 2 year 
questionnaire (Q4). This reduction in 35 patients between Q1 and Q2 and 38 between 
Q2 and Q3 highlights how compliance is affected by this method of administration. 
To encourage patients to return the questionnaire we used stamped addressed 
envelopes and we contacted patients on a second occasion if they had not replied 
within a given time frame. It was felt to be unethical to pursue follow-up any further 
after patients failed to reply to the reminder letter. Compliance might have increased
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if we had contacted patients by phone and administered the questionnaire orally. 
However, this would have introduced unnecessary bias into the study. Despite the 
drop out rate over the two year period, a statistically significant change in QOL after 
surgery was still measured at all 3 time points (Table 4 & 5).
9.2.2 Quality of life after surgery
Global quality of life scores changed significantly following laparoscopic 
cholecystectomy. This supports previous publication that the GIQLI has sufficient 
responsiveness to detect changes in health status after surgery for cholelithiasis 
(Eypasch et ai, 1995; Mentes et al., 2001; Quintana et al, 2003a), and suggests that 
the decision to use the GIQLI instrument in the study was correct. The results provide 
further validation data of the index and for its use in patients with gallstone disease.
Following surgery there was a significant improvement in QOL at the Q2 time 
point and there continued to be slight improvement until Q3 although there was no 
significant difference between the two 1.7 ± 2.2 (p=0.423). The mean improvement of 
Q2 and Q3 was +17.6 points (12.2%). This was higher than the 5 to 10% some 
authors quote as being a significant change in QOL noticeable to patients (Osoba, 
2002), and interestingly is the same value quoted for QOL improvements after 
laparoscopic cholecystectomy in the original validation paper for the index (Eypasch 
et al., 1995). At Q4 there was a significant regression towards the baseline of -7.6 ± 
2.3 (p=0.003) with the mean change in QOL from preoperative levels of +10.8 points 
(7.5%). The majority of published studies examining QOL after laparoscopic 
cholecystectomy have a short follow-up of only 3 to 6 months (Eypasch et al., 1995;
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Mentes et al., 2001; Quintana et ai, 2003a). There is limited data available on long 
term outcome and on whether QOL changes are sustained. Only two papers publish 
long term data (Topcu et al., 2003; Vetrhus et al, 2004), neither of which showed a 
similar pattern of regression seen in this study. As previously discussed both these 
publications are flawed, the Topcu paper for not presenting preoperative QOL data 
and the Vetrhus paper for using an instrument unlikely to be responsive enough to 
detect a significant change.
There are several possible explanations for the regression measured at 2 years. 
Firstly, there could be an initial placebo affect afforded by the surgical intervention, 
with subsequent return of symptoms. There is already published data showing 
significant placebo responses of near 70% in patients with functional dyspepsia 
(Talley et al., 1991), and as can be seen in Figures 11 & 12 a large proportion of study 
patients described these types of symptoms. The Flawthorne effect is similar to the 
placebo effect and could also partly explain these differences (Braunholtz et al., 
2001). It describes changes in patient or clinical behaviour as a result of involvement 
in clinical trials. It is due to increased knowledge or interest in the study or due to the 
patients feeling of being observed. Secondly, the regression may in part be caused by 
complications or side effects of the surgery itself. Laparoscopic cholecystectomy is a 
minimally invasive procedure, but there will undoubtedly be some degree of adhesion 
formation within the peritoneal cavity which may be symptomatic. This, however, is 
unlikely to be cause a regression at 2 years, as adhesions form shortly after surgery 
and are more likely to present earlier. There has also been a reported increase in 
diarrhoea following cholecystectomy that may be persistent (Hearing et al., 1999; 
Sauter et ai. 2002). This may not be apparent at the 3 month time point, but might
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significantly affect QOL when measured at 2 years. As discussed below the GI sub 
domain of the questionnaire did not regress at 2 years and therefore would not support 
this assumption. Thirdly, it is possible that at two years patients who remain 
asymptomatic are less likely to return the final questionnaire. This would leave a 
higher proportion of patients having a worse outcome, resulting in a negative effect on 
the mean QOL at Q4. We know that patients with postcholecystectomy syndrome 
have higher anxiety levels and that the pathogenesis may form part of a somatisation 
disorder (Stefaniak et ai, 2004). This type of patient may be more likely to ruminate 
on symptoms, actively seek medical help and subsequently complete the 
questionnaire. Since IBS is closely related to anxiety and abnormal health seeking 
behaviour we might expect a higher percentage of IBS sufferers to complete Q4. 
Again this assumption is not supported by Figures from this study. 28% of patients 
who returned Q2 had 2 or more Manning symptoms compared to 25% who returned 
Q4, so one might assume this is a true regression in QOL. Lastly, the regression may 
be due to exacerbation of symptoms unrelated to biliary disease, but related to some 
underlying problem such as dyskinesis.
9.2.3 QOL change and domain scores
The four sub-domains of the questionnaire changed in a similar fashion to the 
global score. There was an initial large improvement at Q2 and a smaller but non 
significant increase at Q3 (Tables 6 to 13 and Figures 8 & 9). There was however 
differences observed between Q3 and Q4 for the 4 domains. The improvement 
observed in the GI symptoms domain was maintained to the end of the study period 
57.1 ± 1.1 (p<0.001). This domain contained symptoms such as abdominal pain.
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change in bowel habit, symptoms of dyspepsia and questions related to eating 
(Appendix 2), all of which are important when considering FGID’s and 
postcholecystectomy syndrome. As mentioned above this domain does not account 
for the regression in global score between Q3 and Q4, so side effects of 
cholecystectomy are unlikely to be the explanation for this change. Similarly the 
emotions sub domain had a sustained improvement at Q4 14.1 ±0.4 (p<0.001). This 
domain looks at how patients feel about their illness and how they cope with everyday 
stress. It would appear that laparoscopic cholecystectomy affords significant 
improvement in this area. The remaining two sub-domains showed regression from 
Q3 to Q4. The physical domain showed partial regression -1.8 ± 0.72 (p=0.012) and 
the social domain full regression back to baseline -3.1 ± 0.5 (p<0.001). These 
domains seem to account for the decline in global QOL score observed at two years, 
and suggest that after initial improvement patients find problems with physical 
strength, energy levels and ability to perform normal activities. With no change in the 
GI symptoms domain, this does not appear to relate to recurrent or persistent 
symptoms. It is possible that outside factors such as personal problems, economic 
constraints or social support are influencing these domains (King and Napa, 1998; 
Klose, 2003). It is not possible to give a definitive reason for these differences.
9.2.4 Influence of Manning symptoms on QOL
One of the aims of this prospective study was to show that patients with IBS 
did not experience a significant QOL improvement after surgery. The Manning 
criteria (Table 1) are a set of 6 symptoms used to aid the diagnosis of IBS and they 
were one of the measurements used in the preoperative assessment of the study group.
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At recruitment 32 patients (28.8%) had two or more of the Manning symptoms 
present, with this percentage maintained in the patients who replied to subsequent 
follow-up. Figure 6 shows that approximately 20% of patients remain unchanged or 
have a measured reduction in QOL after surgery. When this group was considered in 
isolation, they were found to have 1.95 ± 0.39 (p=0.037) times the number of 
Manning symptoms compared to the 80% that improved. This goes some way to 
support the hypothesis that patients with IBS do not experience significant QOL 
improvements after laparoscopic cholecystectomy, and was further corroborated, 
when Manning symptoms were correlated with change in QOL after surgery for the 
study group as a whole (Figure 10). Using regression analysis with the mean 
postoperative QOL score as the dependent variable and the mean global score of Q1 
along with Manning symptoms as independent variables there was a 5.2 ± 1.29 
(p<0.001) lower score for every Manning symptom that was present. This means that, 
patients exhibiting three Manning symptoms would be expected to have a global QOL 
score on the G1QLI of around 15 points lower than those who had none. In Figure 10, 
the mean change in QOL is measured along the Y axis, with the red line at zero 
representing no change in QOL. The X axis represents an increasing number of 
Manning symptoms that patients described preoperatively. It can be clearly seen that 
the mean change in QOL reduces towards zero with an increasing number of Manning 
symptoms, and we would expect those patients describing 5 or more of the Manning 
symptoms preoperatively to have no improvement in QOL score after surgery.
From these data it is easy to understand why patients with IBS did not have an 
increase in the QOL score after surgery, but as mentioned earlier a significant 
proportion of patients actually regressed from baseline and had a lower QOL which
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needs some explanation. Firstly, QOL is a dynamic variable (Bergner, 1989; 
Olschewski et ah, 1994), meaning scores will vary from day to day or even hour to 
hour. The recorded negative effect could have simply been a variation of the normal 
QOL experienced by patients who had no improvement after surgery. Secondly, the 
reduced score could also be as a result of an unrealistic expectation from the surgical 
procedure. The results have already shown that patients with IBS have a significantly 
worse outcome after surgery. If these patients had high expectations that intervention 
would cure their symptoms, yet experience little or no benefit from the procedure, 
focusing on persistent complaints may have had a negative effect on outcome. In 
clinical practice it is not uncommon to see patients returning after surgery claiming to 
be worse than ever. I do not have data to support these hypotheses, so a definitive 
answer is outside the scope of these results.
Manning symptoms also had a significant negative effect on all four sub- 
domains of the questionnaire (Table 14). Unsurprisingly, the largest measured effect 
on global QOL (-2.1% for each Manning symptom present) was from the GI 
symptoms domain, which showed a -2.98 ± 0.66 p<0.001 lower domain score for 
each Manning symptom present. With the majority of the Manning symptoms being 
directly measured in this section of the questionnaire and with this domain 
contributing to over 50% of the final score, it was probable that this pattern would be 
observed.
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9.2.5 Influence of preoperative symptoms on QOL
The second aim of this study was to preoperatively identify a group of patients 
unlikely to benefit from intervention. To do this, groups of symptoms were correlated 
with change in QOL using regression analysis in order to predict outcome. The 6 
individual Manning symptoms (Table 15), functional GI symptoms (Table 17), 
variables specific to cholelithiasis (Table 18) and psychiatric history (Figure 14) were 
all examined.
Three of the Manning symptoms were shown to be significant predictors of 
outcome; they were loose bowel movement with onset of pain -17.3 ±4.6 (p<0.001), 
more frequent bowel movement with onset of pain -14.9 ± 5.4 (p=0.007) and pain 
relief with defaecation -14.1 ± 5.3 (p=0.009). The most frequently described Manning 
symptom was abdominal distension. It was recorded in 45 patients (Figure 11) but 
despite a negative effect on outcome it was not shown to have a significant predictive 
value. Interestingly, the three Manning symptoms shown to be significant are the 
three that make up the Rome II criteria. In a similar way to the Manning criteria, the 
21 patients who fulfilled the Rome II criteria had a negative correlation with QOL 
outcome -12.5 ±5.0 (p=0.15). The lower number of IBS patients identified with the 
Rome II criteria corroborates the findings of Saito (Saito et ai, 2000) and our results 
suggest that the Manning criteria are perhaps more sensitive and the Rome II criteria 
more specific at identifying patients with IBS.
Functional GI symptoms were a common finding in the group (Table 17), with 
almost 50% of patients complaining of bloating or troublesome wind. Unlike the 
Manning or Rome symptoms however they were poor at predicting patient outcome.
A feeling of fullness was the only significant symptom recorded, and was in fact the 
only one found to have a significant predictive value for better outcome after 
laparoscopic cholecystectomy +77./ ± 5.2 (p<0.001). One possible explanation was 
poor patient understanding or interpretation of symptoms, which are often vague or 
intermittent. Even for clinicians the classification of functional dyspepsia has been 
confusing in the past (Talley et al, 1991), until more recently when a multinational 
working group clearly defined diagnostic subgroups and symptoms (Talley et al., 
1999). During questioning it was common for patients to confuse symptoms, for 
example, early satiety with anorexia, or tightness and bloating with abdominal 
distension. Despite these being explained during patient assessment, it does raise 
doubts as to the accuracy with which these symptoms were recorded. On the other 
hand these symptoms may be an equally common finding in both patients suffering 
predominantly from gallstones or in those whose primary complaint is functional 
dyspepsia. In terms of QOL, outcome would then be variable. This is supported by 
previous publications stating that relief of functional symptoms following 
laparoscopic cholecystectomy is unpredictable (Bates et al., 1991; human et al., 1996; 
Peterli et al., 2000). In any case, it may have been useful to record these symptoms 
again after surgery, which perhaps could have helped us gain a better understanding 
of the observed changes.
Surprisingly, the three variables specific to cholelithiasis were of no predictive 
value for QOL outcome (Table 18). They all showed a slight increase in mean QOL 
scores after surgery, but these changes were not significant. Of the 45 patients that 
had previous complications from gallstones, 21 had cholecystitis, 11 pancreatitis, 11 
jaundice and 2 cholangitis. It’s difficult to explain why we couldn’t correlate
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significant QOL improvements in this group. In most cases complications were a 
significant time before surgery and perhaps had no affect on baseline QOL at the time 
of interview. Fatty food intolerance is classically described in textbooks as a feature 
of gallstones and for this reason was included in this section. Despite a 5.8 higher 
QOL for patients describing this symptom, there was no significant correlation with 
outcome. This corroborates findings of previous studies that show a weak relationship 
between this symptom and gallstones (Berger et al., 2003). Some studies have shown 
only transient improvement of this symptom after surgery explained by the placebo 
effect of operation (Lire et al., 1995).
Lastly, the effect of a previous or ongoing psychiatric history was examined. It 
had a highly significant effect on outcome with a -21.5 ± 5.2 (p<0.001) lower QOL 
score when present. This correlates well with previous studies that have shown that 
patients with postcholecystectomy syndrome have a higher incidence of anxiety 
(Markert, 1991) and depression (McMahon et al., 1995) and a higher use of 
psychotropic medications (Luman et al., 1996). There is also a strong association 
between IBS and anxiety disorders (Talley and Spiller, 2002). The results showed an 
almost twofold higher psychiatric history in those patients with two or more Manning 
symptoms (Figure 14).
In summary I have been able to show that patients with IBS have a 
significantly worse outcome after laparoscopic cholecystectomy for gallstones. I have 
also been able to demonstrate several symptoms that when present preoperatively, 
have a significant predictive value for poor QOL outcome. Based on these findings 
patients likely to have a less favourable outcome could be identified before having
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surgery. This does not justify a blanket statement for avoiding cholecystectomy in 
patients with IBS. This would require a randomised controlled trial comparing 
treatments along with assessment of outcome in tenns of complication rates from 
gallstones, morbidity and mortality. It does, however, give an opportunity to assess 
what expectations a patient has for surgery and counsel them appropriately. In patients 
with asymptomatic gallstones, complications such as jaundice, pancreatitis and 
cholecystitis are almost always preceded by symptoms (Thistle et a/., 1984; Friedman 
et al., 1989). There is supporting evidence that gallstones have a relatively benign 
natural history and with an onset of symptoms of approximately 1-4% per year, many 
of these patients can be safely treated expectantly (Ransohoff et al., 1983; Friedman, 
1993; Attili et al., 1995b). In patients with IBS, we would recommend that each case 
be evaluated on its own merit, with careful consideration of risk factors, potential 




For the power calculation a 30% drop out rate was predicted based on previous 
mail surveys. At Q2 the drop out rate was actually slightly less than this at 22%; 
however patients failed to respond in similar proportions between Q2 and Q3 and 
again between Q3 and Q4. The final 64 patients who completed Q4 represented 57% 
of those included in the final study analysis, but only 42% of the total initially 
recruited.
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More could have been done to improve the compliance of the study group. 
Firstly patients could have been contacted by telephone (their contact number was 
recorded in the initial pro-forma) to ensure the questionnaire had been received or to 
complete the questionnaire over the phone. The latter may have introduced 
unnecessary bias to the results. Secondly, arrangements could have been made to hand 
deliver questionnaires and complete them in person, or strict outpatient appointments 
could have been made for all those recruited to the study. Both these options would 
have been considerably labour intensive, and the first has ethical issues as patients 
may have felt obliged to answer the questionnaire when they did not want to. Despite 
the relatively poor patient compliance we still showed significant changes in 
postoperative QOL, which correlated well with symptoms of IBS.
9.3.2 Post operative symptoms
It would have been beneficial to repeat the patient pro-forma (Appendix 5) 
after the 2 year follow-up or at each subsequent visit, and record postoperative 
symptoms. This is a fair criticism of the study given that it may have added 
significantly to our understanding and interpretation of the data.
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9.4 Conclusions
This study concludes that:
• A significant proportion of patients with gallstones experience measurable and 
sustained QOL improvements following laparoscopic cholecystectomy.
• The GIQLI shows sufficient responsiveness to be used as a tool for measuring 
QOL outcome in patients with cholelithiasis.
• Patients with symptoms of IBS indicated by the Manning criteria show 
significantly less improvement in QOL following laparoscopic 
cholecystectomy for gallstones.
• The symptoms of loose bowel movement with onset of pain, more frequent 
bowel movement with onset of pain, pain relief with defaecation and a 
previous psychiatric history were significant predictors of poor outcome in 
terms of QOL improvement after laparoscopic cholecystectomy.
These results emphasise that through simple history taking and patient evaluation, we 
can identify individuals likely to have a less favourable outcome after laparoscopic 
cholecystectomy, thus giving us the opportunity to counsel them appropriately.
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9.5 Future directions
This is the first QOL study to show that patients with IBS have a significantly worse 
outcome following laparoscopic cholecystectomy for gallstones. Further research 
should be done to confirm these findings, and to examine treatment options for this 
group of patients. Suggested areas of research include:
1. A larger randomised controlled trial in patients with IBS and gallstones 
comparing QOL outcome after laparoscopic cholecystectomy to other non 
surgical management strategies.
2. Objective parameters of gallbladder disease such as histological changes 
within the gallbladder specimens or preoperative USS findings could be 
compared with QOL improvement following laparoscopic cholecystectomy in 
patients with IBS which might help corroborate our findings.
3. More work should be done at assessing our ability as clinicians to predict 
patients likely to have poor QOL outcome following laparoscopic 
cholecystectomy. Measures could be taken to introduce and validate a scoring 
method to help in this process.
4. It is clear that there is a lack of good QOL research in the field of HPB 
surgery. There are many aspects of both benign and malignant disease that 
have not yet been examined. Presently, there is no universally accepted or 
validated questionnaire specific to this field. It would be beneficial to 
construct, publish and validate such a questionnaire.
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The Gastrointestinal Quality of Life Index (GIQLI)








Please circle the most appropriate answer to ALL of the 36 questions
1) How often during the past 2 weeks have you had pain in the abdomen?
AH of the time , most of the time, some of the time , a little of the time , never
2) How often during the past 2 weeks have you had a feeling of fullness in the upper 
abdomen?
All of the time, most of the time , some of the time , a little of the time , never
3) How often in the past 2 weeks have you had bloating (sensation of too much gas in 
the abdomen)?
AH of the time, most of the time , some of the time , a little of the time , never
4) How often during the past 2 weeks have you been troubled with excessive passage of 
gas through the anus?
All of the time, most of the time , some of the time, a little of the time , never
5) How often during the past 2 weeks have you been troubled by strong burping or 
belching?
All of the time, most of the time , some of the time , a little of the time , never
6) How often during the past 2 weeks have you been troubled by gurgling noises from 
the abdomen?
All of the time, most of the time , some of the time , a little of the time , never
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7) How often during the past 2 weeks have you been troubled by frequent bowel 
movements?
AH of the time, most of the time , some of the time , a little of the time , never
8) How often during the past 2 weeks have you found eating a pleasure?
All of the time, most of the time , some of the time , a little of the time , never
9) Because of your illness, to what extent have you restricted the kind of food you eat? 
Very much , much , somewhat, a little , not at all
10) During the past 2 weeks, how well have you been able to cope with everyday stress? 
Extremely poorly , poorly , moderately , well, extremely well
11) How often during the past 2 weeks have you been sad about being ill?
All of the time, most of the time , some of the time , a little of the time , never
12) How often during the past 2 weeks have you been nervous or anxious about your 
illness?
AH of the time, most of the time , some of the time , a little of the time , never
13) How often during the past 2 weeks have you been happy with life in general?
Never , a little of the time , some of the time , most of the time , all of the time
14) How often during the past 2 weeks have you been frustrated with your illness?
AH of the time, most of the time , some of the time , a little of the time , never
15) How often during the past 2 weeks have you been tired or fatigued?
All of the time, most of the time , some of the time , a little of the time , never
16) How often during the past 2 weeks have you felt unwell?
AH of the time, most of the time, some of the time , a little of the time, never
17) Over the past 2 week, have you woken up in the night?
Every night, 5-6nights, 3-4nights , l-2nights , never
18) Since becoming ill have you been troubled by changes in your appearance?
A great deal, a moderate amount, somewhat, a little hit, not at ad
19) Because of your illness how much physical strength have you lost?
A great deal, a moderate amount, some , a little hit, none
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20) Because of your illness, to what extent have you lost your endurance?
A great deal, a moderate amount, somewhat, a little hit, not at all
21) Because of your illness, to what extent do you feel unfit?
Extremely unfit, moderately unfit, somewhat unfit, a little unfit ,fit
22) During the past 2 weeks, how often have you been able to complete your normal daily 
activities (school, work , household etc..)?
All of the time, most of the time, some of the time , a little of the time , never
23) During the past 2 weeks, how often have you been able to take part in your usual 
patterns of leisure or recreational activities?
AH of the time, most of the time , some of the time , a little of the time , never
24) During the past 2 weeks, how much have you been troubled by the medical treatment 
of your illness?
Very much , much , somewhat, a little , not at ad
25) To what extent have your personal relations with people close to you (family and 
friends) worsened because of your illness?
Very much , much , somewhat, a little, not at all
26) To what extent has your sexual life been impaired ( harmed ) because of your illness? 
Very much , much , somewhat, a little , not at all
27) How often during the past 2 weeks, have you been troubled by fluid or food coming 
back up into your mouth (regurgitation)?
AH of the time, most of the time , some of the time, a little of the time , never
28) How often during the past 2 weeks have you felt uncomfortable because of your slow 
speed of eating?
All of the time, most of the time, some of the time , a little of the time, never
29) How often during the past 2 weeks have you had trouble swallowing your food?
All of the time, most of the time , some of the time , a little of the time , never
30) How often during the past 2 weeks have you been troubled by urgent bowel motions? 
All of the time, most of the time, some of the time , a little of the time , never
31) How often during the past 2 weeks have you been troubled by diarrhoea?
All of the time, most of the time , some of the time , a little of the time, never
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32) How often during the past 2 weeks have you been trouble by constipation?
All of the time, most of the time , some of the time , a little of the time , never
33) How often during the past 2 weeks have you been troubled by nausea?
AH of the time, most of the time , some of the time , a little of the time , never
34) How often during the past 2 weeks have you been troubled by blood in the stools? 
All of the time, most of the time, some of the time, a little of the time, never
35) How often during the past 2 weeks have you been troubled by heartburn?
All of the time, most of the time , some of the time , a little of the time , never
36) How often during the past 2 weeks have you been troubled by uncontrolled stools? 
AH of the time, most of the time , some of the time , a little of the time , never
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Verbal Consent Form
Title: Quality of life measurement following laparoscopic
ch olecystectomy
You are invited to take part as a volunteer in the above research study. You are 
free to decline to participate without giving a reason. If you decide not to take part, 
your decision will be accepted without question or displeasure and you will be treated 
as though the matter had not arisen, without disadvantage to your future care.
If you do agree to participate in the study, you are free to withdraw at any 
time, without giving reason or explanation. Withdrawal will be accepted without 
question or displeasure and without any disadvantage to your future care.
As part of the research study you will be asked to complete four short 
questionnaires, which focus on aspects of your illness and its impact on your daily 
activities. The gallbladder specimen removed at the time of surgery will also be 
examined at the regional pathology department at the Royal Victoria Hospital.
Information gathered during the course of the study will remain confidential, 




Please read the patient information sheet provided before you give consent to take 
part in this study.
Research Co-ordinator
I have explained the nature and purpose of the study to the above subject and he/she 
has freely given consent
Signed_____________________ (research co-ordinator) Date___________ _
Name (print)__________________________
Witnessed verbal consent:
The above named patient has given verbal consent to participate in the above study in 
accordance with the terms outlined above.
Signed__________________________________ (witness) Date_______________
Name of Witness (print)________________________________________________
Appendix 3: Verbal Consent Form
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Patient Information Sheet
“Quality of life following laparoscopic 
cholecystectomy”
You are being invited to take part in a research study. Before you decide it is 
important for you to understand why the research is being done and what it will 
involve. Please take time to read the following information carefully and discuss it 
with others if you wish. Ask us if there is anything that is not clear or if you would 
like more information. Take time to decide whether or not you wish to take part.
You have been asked to take part in this study because you are about to undergo a 
keyhole operation to have your gallbladder removed. The purpose of this study is to 
measure how well your symptoms improve after the operation. This will be done by 
asking you a series of questionnaires relating to your illness. The answers to the 
questions will be given a score enabling us to quantify your “Quality of Life”.
You will be asked to complete the questionnaire before your surgery and repeat the 
same questionnaire at 6 weeks, 3 months and 2 years after your operation. The 
questionnaire consists of 36 short questions relating aspects of your illness, how you 
are feeling, what symptoms you are experiencing and how it impacts on your daily 
life. The questionnaire takes on average 10 minutes to complete. You are given 5 
possible answers to each question, and asked to indicate the most appropriate 
response.
You will not be asked to give blood or take part in any other investigation as part of 
this study, but they may be needed as part of your normal ward treatment.
It is up to you to decide whether or not to take part. If you do decide to take part you 
will be given this information sheet to keep and be asked to sign a consent form. If you 
decide to take part you are still free to withdraw at any time and without giving a 
reason. A decision to withdraw at any time, or a decision not to take part, will not 
affect the standard of care you receive.
Thank you for taking the time to read this information. If you are kind enough to 
agree to take part in this study, I would like to remind you that all information which 
is collected about you during the course of the research will be kept strictly 
confidential. Any information about you which leaves the hospital will have your 
name and address removed so that you cannot be recognised from it.
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Please note that the research ethics committee is auditing patient’s views of the 
research process and you may be asked to complete a questionnaire about your 
experiences.
If you have any further questions do not hesitate to ask, please contact Mr Gareth Kirk 
in the Department of Surgery, Queen’s University of Belfast (phone 02890 240503 
ext 2660)
Appendix 4: Patient information sheet
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GP/A&E / Inpatient/ Other




Main Site of Pain
Pain >3 months q y □ N Nausea DY DN Vomiting □ Y □ N
(within the last year)
□ RUQ □ Upper (Midline) □ Other specify______________________
Radiation of Pain □ Back □ Shoulder Tip □ Other Specify_
Currently on Rx □ Y I I N Brief details _______________________
eg Buscopan, Colofac , Losec, Paracodol etc ..
Cholelithiasis
Proven Gallstones □ Y □ N Previous Abnormal 
LFT's
□ Y □ N FHx of Gallstones i—i y i—i ki (1st/2nd Degree) ^ ^
Fat Intolerance □ Y □ N Previous Complication □ Y □ N
Specify______________________
eg Jaundice , Pancreatitis, Cholecystitis etc..
IBS
Previous Dx





□ Y □ N
FHx of IBS (1st/2nd 
Degree) □ Y
□ Y □ N
More frequent stools 
with onset of pain □ Y
□ Y □ N Mucous □ Y
□ N
Actual Abdominal 
Distention □ Y □ N
□ N Looser stools with onset of pain □ Y □ N
□ N Abnormal Defecation □ Y □ N
Specify
eg Incomplete evacuation , Straining etc ..
Functional Dyspepsia ( Gastroduodenal Disorder)
Organic disease 
excluded
(Via OGD +/- Ba Meal)
□ Y □ N Early Satiety
(Overfull quickly)
□ Y □ N Fullness □ Y | | N
(Unpleasant sensation like food in 
the stomach with or without eating)
Bloating
'Tightness with NO visible 
swelling)
□ Y □ N Previous eradication 
therapy
□ Y □ N Relief with 
eradication
□ Y □ N
Troublesome
Belching □ Y □ N Significant Heartburn □ Y □ N Dysphagia □ Y □ N
Laparoscopic Cholecystectomy QOL Pro-Forma
Psychiatric History
Psychiatric History Qy Psychotropic Rx Qy Qm Brief Details
Questionnaire Pre'°P 6 week« Po^P 3 months Post-Op
Completed DYES □ YES DYES
2 years Post-Op
□ YES
Comments or Other Information
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